

eISBN: 978-1-68108-309-4

ISBN: 978-1-68108-310-0

eISSN: 2405-741X

ISSN: 2405-7401

**FRONTIERS IN NEUROSURGERY**

# **BRAIN ISCHEMIC STROKE - FROM DIAGNOSIS TO TREATMENT**

**VOLUME 3**



**Editor:**  
**Simone Peschillo**

**Bentham  Books**

**Frontiers in Neurosurgery**  
*Volume 3*  
***Brain Ischemic Stroke - From***  
***Diagnosis to Treatment***

**Edited by**

**Simone Peschillo**

*Department of Neurology and Psychiatry*  
*Endovascular Neurosurgery/Interventional Neuroradiology*  
*'Sapienza' University of Rome*  
*Rome*  
*Italy*

**Series Title: Frontiers in Neurosurgery**

ISSN (Online): 2405-741X

ISSN (Print): 2405-7401

**Volume Title: Brain Ischemic Stroke - From Diagnosis to Treatment**

Volume # 3

Editor: Simone Peschillo, M.D., PhD.

ISBN (Online): 978-1-68108-309-4

ISBN (Print): 978-1-68108-310-0

© 2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
  - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
  - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

#### **Bentham Science Publishers Ltd.**

Executive Suite Y - 2  
PO Box 7917, Saif Zone  
Sharjah, U.A.E.  
Email: [subscriptions@benthamscience.org](mailto:subscriptions@benthamscience.org)



# CONTENTS

<b>FOREWORD</b> .....	i
<b>PREFACE</b> .....	v
<b>LIST OF CONTRIBUTORS</b> .....	vii
<b>CHAPTER 1 EPIDEMIOLOGY AND SOCIAL COSTS</b> .....	3
<i>Uo qpg'Rguej kmq'c'pf 'Htcpegueq'Fkpc</i>	
<b>INTRODUCTION</b> .....	4
<b>DEFINITION</b> .....	4
<b>EPIDEMIOLOGY</b> .....	5
Risk Factors .....	7
Unmodifiable Risk Factors: .....	7
Modifiable Risk Factors: .....	7
<b>PREVENTION</b> .....	8
<b>INCIDENCE, PREVALENCE AND MORTALITY</b> .....	10
<b>SOCIETAL COSTS</b> .....	12
<b>ENDOVASCULAR TREATMENT AND VENOUS FIBRINOLYSIS: SOCIO-ECONOMIC COMPARISON</b> .....	16
<b>WHICH ENDOVASCULAR TREATMENT TO USE?</b> .....	20
<b>CONCLUSION</b> .....	21
<b>CONFLICT OF INTEREST</b> .....	21
<b>ACKNOWLEDGEMENTS</b> .....	21
<b>REFERENCES</b> .....	21
<b>CHAPTER 2 BRAIN ISCHEMIA AND STROKE: MECHANISMS AND OPPORTUNITIES</b> .....	23
<i>Htcpegueq'Qt/R'c'pf 'Dctdctc'Ecuqmc</i>	
<b>ABSOLUTE DEPENDENCE ON BLOOD FLOW</b> .....	23
<b>HETEROGENEOUS ORGAN</b> .....	25
<b>ISCHEMIC CORE</b> .....	25
<b>CYTOTOXIC AND VASOGENIC EDEMA</b> .....	27
<b>NECROSIS AND PROGRAMMED CELL DEATHS</b> .....	28
<b>MATURATION PHENOMENON</b> .....	29
<b>PERINECROSIS AREAS</b> .....	30
<b>MECHANISMS ASSOCIATED WITH ISCHEMIC DAMAGE</b> .....	32
<b>DOUBLE SWORD PROCESS</b> .....	35
<b>EVIDENCE LINKING STROKE AND INFLAMMATION</b> .....	36
<b>NOT JUST A LOCAL EVENT</b> .....	37
<b>DIFFERENTIATING PRO-LIFE AND PRO-DEATH MECHANISMS</b> .....	38
<b>OPPORTUNITIES</b> .....	40
<b>BOXES</b> .....	41
Box 1 Theoretical Models for Measuring Cerebral Blood Flow and Metabolism .....	41
Box 2 NMDA Receptors .....	43
Box 3 Programmed Cell Deaths .....	43
Box 4 Oxidative Stress .....	46
Box 5 Complement, Ficolins and MBL .....	46
Box 6 Adhesion Molecules .....	48
Box 7 Lymphocytes and Stroke .....	48
<b>CONFLICT OF INTEREST</b> .....	49
<b>ACKNOWLEDGEMENTS</b> .....	49

REFERENCES .....	50
<b>CHAPTER 3 NEW IMAGING TECHNIQUES</b> .....	55
<i>Grgpc 'Hqpvpc. 'Crguacpf tq'Dqgnku. 'Nct c'Etlnkcpq'cpf 'Crguacpf tq'Dq  cq</i>	
INTRODUCTION .....	55
PATHOPHYSIOLOGY .....	57
CEREBRAL VASCULAR TERRITORIES AND CLINICAL PRESENTATION .....	58
IMAGING .....	63
Acute Phase .....	63
Computed Tomography (CT) .....	63
Magnetic Resonance Imaging (MRI) .....	73
Subacute Phase .....	78
Computed Tomography (CT) .....	78
Magnetic Resonance Imaging (MRI) .....	80
Chronic Phase .....	81
Computed Tomography (CT) .....	81
Magnetic Resonance Imaging (MRI) .....	82
VENOUS INFARCT .....	84
THERAPY: THE ROLE OF IMAGING .....	85
CONFLICT OF INTEREST .....	87
ACKNOWLEDGEMENTS .....	87
REFERENCES .....	87
<b>CHAPTER 4 MEDICAL ACUTE STROKE TREATMENT</b> .....	95
<i>Rcqrq'Ecpf grt guk'cpf 'Chtpuq'Ekeqpg</i>	
INTRODUCTION .....	95
GENERAL SUPPORTIVE CARE .....	96
STROKE UNIT .....	98
INTRAVENOUS THROMBOLYSIS .....	100
SYMPTOMATIC HEMORRHAGIC TRANSFORMATION .....	105
INTRAVENOUS THROMBOLYSIS IN THE REAL WORLD: BEYOND CONTRAINDICATIONS?	
.....	107
NEW THROMBOLYTIC AGENTS AND NEW MEDICAL REPERFUSION STRATEGIES .....	113
CONCLUSION .....	116
CONFLICT OF INTEREST .....	117
ACKNOWLEDGEMENTS .....	117
REFERENCES .....	117
<b>CHAPTER 5 ENDOVASCULAR STROKE THERAPY: DEVICES AND DIFFERENT APPROACHES</b> .....	122
<i>Fcpkgrg'I OTqo cpq. 'Uto wgrg'Ekqp'k'cpf 'U:pf tc'Dtceeq</i>	
INTRODUCTION .....	122
SELECTION PATIENTS FOR ENDOVASCULAR TREATMENT .....	124
Recent Trials .....	130
ENDOVASCULAR RECANALIZATION STRATEGIES .....	131
ENDOVASCULAR MECHANICAL THROMBECTOMY .....	132
Mechanical Thrombectomy Devices .....	134
MERCi .....	134
STENT-TRIEVERS .....	134
Solitaire FR .....	135
TREVO .....	138
REVIVE .....	139
Tromboaspirating Devices .....	139
PENUMBRA SYSTEM .....	141

COMBINED SUCTION EMBOLLECTOMY AND MECHANICAL RETRIEVAL .....	146
CONFLICT OF INTEREST .....	147
ACKNOWLEDGEMENTS .....	147
REFERENCES .....	147

**CHAPTER 6 MECHANICAL THROMBECTOMY FOR ACUTE ISCHEMIC STROKE: REVIEW OF THE**

*Kcrtq'Npkrpvg*

<b>EVIDENCE</b> .....	152
<b>INTRODUCTION</b> .....	153
<b>SYNTHESIS-EXPANSION</b> .....	154
Interventional Management of Stroke (IMS III) .....	154
The Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) .....	155
The Solitaire FR with the Intention for Thrombectomy (SWIFT) Trial .....	157
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO) .....	158
Multicenter Randomized Clinical Trial of Endo-vascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) .....	158
Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times (ESCAPE) .....	159
Extending the Time for Thrombolysis in Emergency Neurological Deficits — Intra-Arterial (EXTEND-IA) .....	161
Solitaire FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) .....	163
Randomized Trial of Revascularization with Solitaire FR Device versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting within Eight Hours of Symptom Onset (REVASCAT) .....	164
<b>CASE EXAMPLE</b> .....	164
<b>CONCLUSION</b> .....	166
<b>CONFLICT OF INTEREST</b> .....	167
<b>ACKNOWLEDGEMENTS</b> .....	167
<b>REFERENCES</b> .....	167

**CHAPTER 7 NEUROSURGERY IN BRAIN ISCHEMIC STROKE** .....

*Rcqrq'Okaqt'k'cpf'Etka'kpc'O'cpect'gmv*

<b>INTRODUCTION</b> .....	170
Microsurgical Embolectomy .....	171
Decompressive Craniectomy .....	173
<b>MOYAMOYA DISEASE</b> .....	176
Case Illustration .....	178
<b>CONFLICT OF INTEREST</b> .....	179
<b>ACKNOWLEDGEMENTS</b> .....	179
<b>REFERENCES</b> .....	179

**CHAPTER 8 CLINICAL, PHARMACOLOGICAL AND ENDOVASCULAR MANAGEMENT OF CEREBRAL VENOUS THROMBOSIS** .....

*Hgf'gt'keq'F'k'O'ct'k.'H'qt'g'D'ct'q'p'p'g'v'E'j'c'w'x'g'v'E'j'c't'q'w'g'T'q'u'u'q'c'p'f'H'f'g'f'g't'k'e'E'r'c't'g'p'±'q'p*

<b>INTRODUCTION</b> .....	186
Clinical Presentation .....	186
Risk Factors and Clinical Work-up .....	186
Outcome and Late Complications .....	188
<b>IMAGING DIAGNOSIS</b> .....	190
Computed Tomography .....	190
Complications: Imaging Findings .....	194
CT Venography .....	195
Magnetic Resonance Imaging .....	195



MR Venography .....	198
Angiographic Findings .....	199
Predictive Factors of Clinical Deterioration .....	200
CT, MRI, DSA: Comparison .....	200
<b>MANAGEMENT AND TREATMENT</b> .....	201
Anticoagulation .....	201
Intracranial Hypertension Treatment .....	202
Specific Treatments .....	202
Rescue Treatments .....	203
<b>ENDOVASCULAR TREATMENT OF CEREBRAL VENOUS THROMBOSIS</b> .....	203
<b>CONCLUSION</b> .....	209
<b>ACKNOWLEDGEMENTS</b> .....	209
<b>CONFLICT OF INTEREST</b> .....	209
<b>REFERENCES</b> .....	209

**CHAPTER 9 INTRACRANIAL STENOSIS: MEDICAL AND ENDOVASCULAR MANAGEMENT** .... 215

<i>Cɹɹuɹpftq'Ugeeq'ɹpf'Rɹqɹ'Ocej·</i>	
<b>INTRODUCTION</b> .....	215
<b>NEUROIMAGING OF ICAS</b> .....	215
<b>MEDICAL THERAPY IN ICAS</b> .....	221
<b>RISK FACTORS MODIFICATION</b> .....	223
<b>ENDOVASCULAR THERAPY IN ICAS</b> .....	224
Angioplasty .....	224
Stenting .....	224
<b>SAMMPRIS</b> .....	225
<b>RECOMMENDED TREATMENT</b> .....	226
<b>NOTES</b> .....	228
<b>CONFLICT OF INTEREST</b> .....	229
<b>ACKNOWLEDGEMENTS</b> .....	229
<b>REFERENCES</b> .....	229

**CHAPTER 10 UNCOMMON CAUSE OF STROKE: DIAGNOSIS AND TREATMENT (PART I)** ..... 237

<i>Rɹqɹ'Egttcvq.'Cɹɹuɹpftq'Rgl kpk'ɹpf'1kqxcppc'Xcwrɹ</i>	
<b>COLLAGEN VASCULAR DISORDERS AND OTHER NON INFLAMMATORY VASCULOPATHIES</b> .....	238
<b>FIBROMUSCULAR DYSPLASIA</b> .....	238
Clinical Findings .....	240
Diagnostic Assessment .....	242
Treatment .....	243
<b>EHLERS-DANLOS SYNDROME (EDS)</b> .....	244
Clinical Findings .....	244
Cerebrovascular Features .....	246
Brain and Spine Structural Anomalies .....	248
Treatment .....	249
<b>MARFAN SYNDROME</b> .....	250
Cerebrovascular Complications .....	252
Treatment .....	253
<b>OSTEOGENESIS IMPERFECTA</b> .....	254
Clinical Findings .....	254
Neurological Features .....	256
Diagnosis .....	256
<b>NEUROFIBROMATOSIS</b> .....	256
Cardiovascular Findings .....	257

Cerebrovascular Complications .....	257
Treatment .....	259
<b>PSEUDOXANTHOMA ELASTICUM</b> .....	259
Clinical Features .....	260
Vascular Complications .....	261
Diagnosis and Treatment .....	262
<b>POLYCYSTIC KIDNEY DISEASE</b> .....	263
Hypertension and Cardiac Manifestations .....	264
Cerebrovascular Manifestations .....	264
Treatment .....	266
<b>SNEDDON SYNDROME</b> .....	266
Clinical Features .....	267
<i>Dermatologic Manifestations</i> .....	267
<i>Neurological Features</i> .....	267
<i>Cardiac Features</i> .....	269
<i>Diagnostic Assessment</i> .....	270
<i>Treatment</i> .....	271
<b>MOYA-MOYA DISEASE</b> .....	271
General Features and Classification .....	272
Pathogenesis .....	273
Clinical Features .....	273
Diagnosis .....	274
Treatment .....	277
<b>CERVICAL ARTERY DISSECTION</b> .....	278
Pathogenesis .....	279
Genetics of CAD .....	283
Clinical Manifestations .....	284
Diagnosis .....	286
<i>Ultrasound and Neuroradiological Tools</i> .....	286
<i>Skin Biopsy and Other Advanced Diagnostic Tools</i> .....	288
Treatment .....	289
<i>Medical Treatment</i> .....	289
<i>Interventional Procedures</i> .....	290
<i>Surgery</i> .....	291
<i>Prognosis</i> .....	291
<b>VASCULITIS OF THE CENTRAL NERVOUS SYSTEM</b> .....	291
Primary Angiitis of the Central Nervous System (PACNS) .....	293
Granulomatous Angiitis of The CNS .....	295
Angiographically Defined PACNS .....	297
Cerebral Amyloid Angiopathy Related Angiitis .....	297
Secondary Angiitis of The CNS .....	298
Treatment of PACNS .....	300
<b>REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME</b> .....	300
Diagnostic Assessment in RCVS .....	304
Treatment .....	306
<b>VASCULITIS IN CHILDREN</b> .....	307
Primary CNS vasculitis in children .....	307
Transient Cerebral Arteriopathy and Postvaricella Angiopathy in Children .....	307
<b>GIANT CELL ARTERITIS</b> .....	309
Systemic Features .....	310
Visual Features .....	311

Neurological and Cerebrovascular Manifestations .....	312
Diagnostic Assessment .....	314
Treatment and Course .....	315
<b>TAKAYASU'S ARTERITIS</b> .....	316
Clinical Features and Differential Diagnoses .....	319
Diagnostic Assessment .....	320
Treatment .....	321
<b>BEHÇET DISEASE</b> .....	323
General Features .....	323
Neurological Features .....	325
Diagnostic Assessment .....	327
<i>Neuroimaging</i> .....	327
<i>Cerebrospinal Fluid Examination</i> .....	328
<i>Treatment</i> .....	328
<i>SUSAC'S SYNDROME</i> .....	329
<i>Clinical Findings</i> .....	330
Diagnostic Assessment .....	331
<i>Neuroradiological Features</i> .....	331
<i>Optical Coherence Tomography (OCT)</i> .....	333
<i>Fluorescein Angiography of The Retina</i> .....	333
<i>Differential Diagnosis</i> .....	334
<i>Treatment</i> .....	334
<i>Course and Prognosis</i> .....	335
<b>COGAN SYNDROME</b> .....	335
Clinical Findings .....	336
Audiovestibular Manifestations .....	337
Ocular Manifestations .....	337
Systemic Manifestations .....	338
Neurological Manifestations .....	338
Therapeutic Approaches .....	339
Angiotropic Large Cell Lymphoma .....	340
Neurological Features .....	340
Diagnostic Assessment .....	341
Treatment .....	343
<b>CLIPPERS SYNDROME</b> .....	344
Diagnosis .....	345
Treatment .....	346
<b>ACKNOWLEDGEMENTS</b> .....	346
<b>CONFLICT OF INTEREST</b> .....	347
<b>REFERENCES</b> .....	347
<b>CHAPTER 11 UNCOMMON CAUSE OF STROKE: DIAGNOSIS AND TREATMENT (PART II)</b> .....	376
<i>Rcqrq'Eggtcvq.'Crguacpftq'Rg  lpk'bpf 'I lqxcppc'Xcwr</i>	
<b>HEREDITARY CEREBRAL SMALL VESSELS DISEASES</b> .....	377
<b>CADASIL</b> .....	377
<b>PATHOGENESIS</b> .....	378
Clinical Phenotype .....	379
Neuroimaging .....	380
<b>COL4 A1/2 RELATED DISORDERS</b> .....	383
Pathogenesis .....	383
Clinical Phenotypes .....	384
Neuroimaging .....	387

<b>CARASIL</b> .....	387
Clinical Phenotype .....	388
Neuroimaging .....	389
<b>CEREBRORETINAL VASCULOPATHIES AND RELATED DISEASES</b> .....	389
Clinical Phenotype .....	390
Neuroimaging .....	391
Pathology .....	392
<b>CEREBRORETINAL MICROANGIOPATHY WITH CALCIFICATIONS AND CYSTS</b> .....	392
Clinical Phenotype .....	393
Neuroimaging .....	393
<b>STROKE AND METABOLIC DISEASES</b> .....	394
Fabry Disease .....	394
General Findings .....	394
Cerebrovascular Complications .....	397
Treatment .....	399
Homocystinuria .....	400
Clinical Findings .....	402
Vascular Complications .....	403
Diagnosis .....	404
Treatment .....	405
Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) .....	406
Clinical Features .....	406
Neurological Complications .....	407
Radiological Features .....	408
Metabolic and Pathological Features .....	409
Treatment .....	409
<b>ISCHAEMIC STROKE AND ANTIPHOSPHOLIPID SYNDROME</b> .....	410
Clinical Criteria .....	410
Vascular Thrombosis .....	410
Obstetric Complications .....	411
Other Features .....	411
Laboratory Criteria .....	411
Lupus Anticoagulant .....	412
Anticardiolipin (aCL) Antibodies .....	412
Anti $\beta$ 2-Glycoprotein I (a $\beta$ 2GPI) Antibodies .....	412
Cerebrovascular Complications .....	413
Pathology and Pathophysiology .....	414
Embolic Sources .....	415
Valve Abnormalities .....	415
Intracardiac Thrombi .....	417
Treatment .....	417
Primary Prevention .....	418
Secondary Prevention .....	418
Catastrophic APS .....	420
<b>SICKLE-CELL DISEASE</b> .....	420
Neurologic Complications .....	420
Diagnostic Assessment .....	422
Treatment .....	423
<b>OTHER UNCOMMON CAUSES OF STROKE</b> .....	426
Acute Posterior Multifocal Placoid Pigment Epitheliopathy .....	426
Neurological Features .....	427

Diagnostic Assessment .....	427
The Differential Diagnosis .....	428
Treatment .....	429
Malignant Atrophic Papulosis (Köhlmeier-Degos) .....	429
<i>Clinical Findings and Neurologic Features</i> .....	430
<i>Diagnosis and Treatment</i> .....	431
<b>STROKE AND MIGRAINE</b> .....	432
Migraine With Aura and Transient Ischemic Attack .....	432
Migrainous Stroke .....	435
Silent Cerebral Ischemic Lesion in Migraine .....	437
Secondary Migraine With Aura and Ischaemic Stroke .....	438
Practical Implications of The Migraine–Stroke Association .....	439
<b>CEREBROVASCULAR COMPLICATION OF DRUGS ABUSE</b> .....	440
Heroin .....	441
Cocaine .....	443
Cannabis .....	445
Phenylpropranolamine and Ephedrine .....	447
<b>CONFLICT OF INTEREST</b> .....	449
<b>ACKNOWLEDGEMENTS</b> .....	449
<b>REFERENCES</b> .....	449

## **CHAPTER 12 ENDOVASCULAR MANAGEMENT OF ATHEROSCLEROTIC AND DISSECTED**

<b>CAROTIDS</b> .....	474
<i>I wi nkro q'Rgt q'cpf 'Vj go kaqmk' Rrc culogne u</i>	
<b>INTRODUCTION</b> .....	474
<b>INDICATIONS OF CAROTID STENTING</b> .....	476
Patient Related Factors .....	476
Anatomy Related Factors .....	476
<b>ENDOVASCULAR TECHNIQUE AND MATERIALS</b> .....	478
<b>COMPLICATIONS</b> .....	486
<b>PHARMACOLOGICAL SUPPORT</b> .....	488
<b>CAROTID DISSECTIONS</b> .....	490
<b>CONCLUSION</b> .....	493
<b>CONFLICT OF INTEREST</b> .....	494
<b>ACKNOWLEDGEMENTS</b> .....	494
<b>REFERENCES</b> .....	494

## **CHAPTER 13 INTENSIVE CARE MANAGEMENT**

<i>Hgf gteq 'Dkaqwc. 'O ct wpc 'P qxgnk 'Hkr r q'Rgeqt ct k'cpf 'I kaxcppk' T quc</i>	
<b>INTRODUCTION</b> .....	498
<b>GENERAL SUPPORTIVE CARE AND TREATMENT OF ACUTE COMPLICATIONS</b> .....	499
Ventilation and Supplement Oxygen .....	499
Sedation and Analgesia .....	500
Blood Pressure .....	501
Fluid Management .....	502
Myocardial Complications .....	503
Glycemic Control .....	503
Temperature .....	503
Thromboprophylaxis .....	504
Anemia .....	504
Hemorrhagic Transformation .....	504
Cerebral Edema .....	504
Seizures .....	505

Neuromonitoring .....	506
<b>CONCLUSION</b> .....	506
<b>ACKNOWLEDGEMENTS</b> .....	506
<b>CONFLICT OF INTEREST</b> .....	507
<b>REFERENCES</b> .....	507
<b>CHAPTER 14 THE TRIALS AND TRIBULATIONS OF ISCHEMIC STROKE THERAPY</b> .....	511
<i>Ct c p k D q u g . ' U j r j k ' U M M u q . ' L g p p h g t ' Y q p i . ' L q j p ' N q e n j c t v ' c p f ' U w ' R q ' U w</i>	
<b>OVERVIEW</b> .....	511
<b>DEVICES AND CLINICAL TRIALS IN ACUTE ISCHEMIC STROKE</b> .....	512
The Beginning of Mechanical Thrombectomy .....	512
Aspiration Thrombectomy Comes of Age .....	513
The Advent of Stent Retrievers .....	514
Combination Techniques Evolve .....	514
The Early Inconclusive Mechanical Thrombectomy Trials .....	516
Early and Rapid Reperfusion are Critical for Good Clinical Outcomes .....	516
The Benefits of Intra-Arterial Therapy are Confirmed .....	517
<b>SUMMARY</b> .....	522
<b>CONFLICT OF INTEREST</b> .....	524
<b>ACKNOWLEDGEMENTS</b> .....	524
<b>REFERENCES</b> .....	525
<b>CHAPTER 15 EVOLUTION OF DEVICES FOR ENDOVASCULAR THROMBECTOMY IN ACUTE ISCHEMIC STROKE: FROM THE BEGINNING TO THE ADAPT TECHNIQUE</b> .....	529
<i>U o q p g ' R g u e j h n j ' c p f ' H t c p e g u e q ' F k p c</i>	
<b>INTRODUCTION</b> .....	529
<b>PHARMACOLOGICAL INTRA-ARTERIAL THROMBOLYSIS</b> .....	533
<b>CLOT-DISRUPTOR</b> .....	534
Second-generation clot removers: the Penumbra aspiration system .....	535
<b>CLOT-CATCHER</b> .....	537
<b>STENT RETRIEVERS</b> .....	537
<b>ADAPT (A DIRECT ASPIRATION FIRST PASS TECHNIQUE)</b> .....	538
The EKOS MicroLysUS Catheter .....	542
<b>FUTURE PERSPECTIVES</b> .....	542
<b>CONFLICT OF INTEREST</b> .....	542
<b>ACKNOWLEDGEMENTS</b> .....	542
<b>REFERENCES</b> .....	543
<b>SUBJECT INDEX</b> .....	546

## FOREWORD

I read with a lot of interest the book by Simone Peschillo and his collaborators. This book presents the current knowledge on cerebral ischaemia and its treatment. It will be for sure very useful for all those who are interested on this topic.

It starts by the very concerning epidemiological and economic aspect of the disease and then it presents all the main themes of the subject. It will be a reference book that aims to be complete and it does not only present the therapeutic endo vascular techniques but also, and it is fundamental, all the medical environment and intensive care techniques which are essential.

We can only admire the progresses made, even in the diagnostic plan. I personally began to practise neuroradiology 45 years ago ... It was the time when the diagnosis of an intracerebral hemorrhage could only be made if this bleeding was voluminous enough to displace the adjacent arteries angiography ...

I had the privilege in 1971 of attending the first french private presentation on CT by Ambrose who showed unrefined images made of black and white spots. It was a revolution : we were able to see directly, for the first time, the image of intracerebral blood. Nowadays, despite of MRI, CT remains a fundamental tool of decision in the field of cerebral ischaemia because it is fast and easily accessible.

In the 70s, there were few interventional neuroradiologists and they were more interested in angiomas and tumors than in cerebral ischaemia. I was personally rapidly interested in this topic and the 80s were very important for me. In 1980 I began using angioplasty to treat major supra aortic arteries, then in 1983, after Mathias [1] I started simple angioplasty in carotid arteries [2]. I described in 1984 the concept of cerebral protection [3]. After Zeumer [4], I also in 1985 performed our first cases of intra arterial thrombolysis [5]. In 1990 I dared to put in place the first carotid stent [6] and then developed this technique [7, 8]. It activated some turbulences in the vascular surgery environment...

I am now delighted that this tool has become a classic in the treatment of carotid stenoses. Nevertheless let me summarize what I keep thinking on this matter:

At the opposite of the other arteries, post stenting restenoses are quite rare in carotid artery because of its high flow. Long closed stents remain for us the best choice because they treat the whole pathological area and correct partially the artery tortuosity.

The only real difficulty that remains is its approach on atheromatous patients. This is why we described the radial approach [9].

*ii*

I keep thinking that a cerebral protection is mandatory and that the only real protection is the temporary occlusion of the distal internal carotid artery [10]. Filters offer a protection only for big emboli and are themselves responsible of emboli. The temporary occlusion of the common carotid artery with simultaneous occlusion of the external carotid artery, that we also have described and later abandoned, seems to be reserved for the treatment of complete occlusions of the internal carotid.

Post revascularisation hemorrhage occurs in most cases on brains with previous silent infarctions. Its occurrence is clearly limited by the control of blood pressure. Actually it can also be a delayed embolic hemorrhagic complication.

The book presents a very detailed chapter on non atheromatous arterial lesions. It is a very interesting topic that covers several diseases. We have been early interested in the disease of Takayasu when we worked in Canada [11] and we performed endovascular treatments on similar cases. More studies will be necessary in the future to adopt a common therapeutic strategy because the reaction to endovascular techniques can be quite different from one disease to the other.

In acute brain ischaemia I have to say my enthusiasm by seeing strengthening in the idea that a cerebrovascular accident is not any more a fate and that it exist therapeutic tools to treat it. After intravenous and intra arterial thrombolysis, mechanical revascularisation technics are now available and are more and more sophisticated and effective. This book presents the various current possibilities. The time will tell us which ones are the best for each case. What is sure is that the number of necessary interventionists will grow dramatically in the future. I am delighted at it for the whole world population.

However I would like to add about this topic some personal ideas that have meant a lot to me for years: we know that it is necessary to save time and CT remains the basic emergency investigation which allows make the diagnosis of intracerebral bleeding. We dreamt of CTs in a light truck and we spoke of it for many years. It does exist presently. If we deal with an ischemic case it will allow start immediately the intravenous thrombolysis. Many lives will be saved and many brains will be less damaged.

Arrived at the hospital, unless a complete clearance of the symptoms has been obtained, the patient will have an angiography. The good therapeutic decision will only be taken if the exact state of the cerebral vascularization is known. The cerebral parenchymography [12] remains for me the simplest and most adapted investigation. One single injection of contrast in the aortic arch is sufficient for confirming the arterial occlusion, its site and the exact devascularisation downstream to the occlusion. Anatomical variations are infinite and so are the individual possibilities of revascularisation. Vascularization of the cerebral parenchyma is



the only true key point to be known

In the decision of treating, occlusion of lenticulostriate arteries is for me a fundamental point. These arteries are terminal and their wall is very sensitive to ischaemia. It has been shown by Kamyjio on cat that their revascularization after the 6th hour resulted in high percentage of bleeding [13]. We have confirmed it [14] in showing that it was possible to eliminate post revascularization hemorrhage : intra arterial thrombolysis should not be performed on a patient after the 6th hour when the lenticulostriate arteries are occluded . On the other hand the therapeutic window can be widened if these arteries are not interested. This way of reasoning is obviously applicable also for the mechanical revascularisation.

Not using these information made that the possible therapeutic window was reduced in order to limitate the hemorrhagic complications. We are convinced that these simple rules should be used by all, day and at night, and that they could save numerous lives and handicaps.

**Dr. Jaques Théron**

Department of Endovascular and Percutaneous Therapy  
Hospital Nuestra Señora del Rosario  
Madrid  
Spain

#### References

- [1] Mathias K. Perkutane transluminale katheterbehandlung supraortler arterienobstruktion. *Angiology* 1981; 3: 47-50.
- [2] Théron J, Raymond J, Casasco A, Courtheoux P. Percutaneous angioplasty of atherosclerotic and post-surgical stenosis of carotid arteries. *AJNR* 1987; 8: 495-500.  
[PMID: 2955682]
- [3] Théron J, Courtheoux P, Alachkar F, Maiza D. New triple coaxial catheter system for carotid angioplasty with cerebral protection. *AJNR* 01990; 11: 869-74.  
[PMID: 2145730]
- [4] Zeumer H, Hackle W, Ringelstein EB. Local intraarterial thrombolysis in vertebrobasilar thrombo-embolic disease. *AJNR* 1083; 4: 401-4.
- [5] Théron J, Courtheoux P, Casasco A, *et al.* The carotid territory. *AJNR* 1989; 10: 753-65.  
[PMID: 2505504]
- [6] Théron J, Guimaraens L, Casasco A, *et al.* Angioplasty of brachiocephalic vessels. In: Vinuela V, Halbach VV, Dion JE, eds. *Interventional neuroradiology: endovascular therapy of the central nervous system*. 1992. p. New York Raven Press.
- [7] Théron J, Payelle G, Coskun O, Huet H, Guymararens L. Carotid artery stenosis: treatment with protected balloon angioplasty and stent placement *Radiology* 1996; 201(3): 627-36.  
[PMID: 8939208]
- [8] Théron J, Guimaraens L, Casasco A, *et al.* "Protected" wallstenting of atheromatous stenoses at the carotid bifurcation. *Interventional Neuroradiol* 2003; 9: 99-126.

- [9] Théron J, Guimaraens L, Casasco A, *et al.* The treatment of supraaortic arterial lesions. *Interventional Neuroradiol* 2007; 13: 133-44.
- [10] Théron J, Reul J, Venturi C, Bedogni F, Milosevic Z. Immediate and mid-term clinical outcome of patients treated with the TwinOne® cerebral protection system - multicentric trial : 209 Cases. *Cardiovasc Interventional Radiol* 2009.
- [11] Theron J, Tyler JL. Takayasu's arteritis of the aortic arch: endovascular treatment and correlation with positron emission tomography. *AJNR* 1987; 8: 621-6.
- [12] Theron J, De Oliveira D, Alachkar F, Maiza D. Dynamic digitalized parenchymography. *Neuroradiology* 1992; 34: 361-4.
- [13] Kamijyo Y, Garcia JH, Cooper J. The cat. A model of hemorrhagic and subcortical infarction. *J Neuropathol Exp Neurol* 1977; 36: 338-50.  
[PMID: 839241]
- [14] Théron J, Coskun O, Huet H, Oliveira G, Toulas P, Payelle P. The carotid territory. *Interventional Neuroradiology* 1996; 2(2): 111-26.  
[PMID: 20682124]

## PREFACE

Someone suffers a stroke every 40 seconds in the USA; every year over 15 million people throughout the world suffer a stroke and 5 million are left significantly disabled. Stroke is thought to be the second biggest killer worldwide, and is responsible for over 5 million deaths per year.

The total economic burden of stroke is of the order of £7billion per annum in England and Wales.

Even though many efforts to treat as much as possible stroke patients have been made, many of it are still left undertreated, mainly due to the short time window and other contraindications for intravenous (i.v.) rtPA. Furthermore, much more evidence demonstrates that endovascular treatment, in selected patients, is much more resolute.

Various strategies have been developed to increase the number of treated patients: regarding the diagnosis, new neuroimaging tools allows neurologists and neurointerventionists to evaluate either the ischemic core and the vessel pattern and collateral status; regarding medical treatment, new molecules are being tested in RCTs (randomized clinical trials) with extended time windows.

In this context, endovascular treatment is a new technique that allows neurointerventionists to treat patients in whom intravenous rtPA has failed and those in extended time windows, in particular in large-vessels occlusion.

Regarding this novel approach, a new era has emerged with new devices (*i.e.* stent-retrievers and aspiration techniques), which have demonstrated in recently published RCTs higher rates of recanalization and clear superiority compared to previous devices.

Several ongoing RCTs are now investigating whether bridging therapy is more effective than i.v. treatment alone, whether mechanical thrombectomy is more successful than the best medical treatment in patients ineligible for i.v. thrombolysis and which kind of endovascular treatment is much effective.

The purpose of this eBook is to take stock of the latest news on the ischemic stroke treatment.

In 2020, mortality will be doubled due to this serious disease; everyone, health care assistants, social assistants and politicians as well, should be first in line to fight this battle.

This eBook is addressed not only to specialists in the treatment of patients with ischemic

*vi*

stroke, but also nurses, physiotherapists and finally non-medical personnel whose task is to decide on health care.

**Dr. Simone Peschillo**

Department of Neurology and Psychiatry  
Endovascular Neurosurgery/Interventional Neuroradiology

'Sapienza' University of Rome

Rome

Italy

## List of Contributors

<b>Alfonso Ciccone</b>	Department of Neurosciences, Carlo Poma Hospital, Mantua, Italy
<b>Alessandro Boellis</b>	NESMOS Department, University of Rome “Sapienza”. S. Andrea Hospital, Rome, Italy
<b>Alessandro Bozzao</b>	NESMOS Department, University of Rome “Sapienza”. S. Andrea Hospital, Rome, Italy
<b>Alessandro Stecco</b>	Neuroradiology Unit, Radiology Dept, Novara Maggiore Hospital, Italy
<b>Alessandro Pezzini</b>	Department of Clinical Science, Neurological Clinical Brescia University, Italy
<b>Arani Bose</b>	Penumbra Inc., Alameda, CA, USA
<b>Barbara Casolla</b>	Department of Neurosciences, Mental Health and Sensory Organs, University of Rome “La Sapienza”, Rome, Italy
<b>Charlotte Rosso</b>	APHP, Urgences Cérébro-Vasculaires, Groupe Hospitalier Pitié-Salpêtrière, 75013, Paris, France Faculté de Médecine, Université Paris 6 “Pierre et Marie Curie” (UPMC), 75005 Paris, France
<b>Cristina Mancarella</b>	Department of Neurology and Psychiatry, Neurosurgery, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy
<b>Daniele G. Romano</b>	Unit of Neurointerventional, Division of Neuroradiology, Department of Neurological and Neurosensorial Sciences, University Hospital of Siena, Italy
<b>Elena Fontana</b>	NESMOS Department, University of Rome “Sapienza”. S. Andrea Hospital, Rome, Italy
<b>Francesco Diana</b>	Department of Radiology, “Sapienza” University of Rome, Rome, Italy
<b>Federico Di Maria</b>	APHP, Service de Neuroradiologie Interventionnelle Groupe Hospitalier Pitié, Salpêtrière, 75013, Paris, France
<b>Flore Baronnet-Chauvet</b>	APHP, Urgences Cérébro-Vasculaires, Groupe Hospitalier Pitié-Salpêtrière, 75013, Paris, France
<b>Frederic Clarençon</b>	APHP, Service de Neuroradiologie Interventionnelle Groupe Hospitalier Pitié, Salpêtrière, 75013, Paris, France APHP, Urgences Cérébro-Vasculaires, Groupe Hospitalier Pitié-Salpêtrière, 75013, Paris, France
<b>Francesco Orzi</b>	Department of Neurosciences, Mental Health and Sensory Organs, University of Rome “La Sapienza”, Rome, Italy
<b>Federico Bilotta</b>	Department of Anesthesiology, Critical care and Pain medicine, “Sapienza” University of Rome, Rome, Italy

<b>Filippo Pecorari</b>	Department of Anestehsiology, Critical care and Pain medicine, “Sapienza” University of Rome, Rome, Italy
<b>Giovanna Vaula</b>	Stroke Unit, Department of Neuroscience, Turin University Molinette Hospital, Turin, Italy
<b>Guglielmo Pero</b>	Department of Neuroradiology, Niguarda Ca’ Granda Hospital, Milan, Italy
<b>Giovanni Rosa</b>	Department of Anestehsiology, Critical care and Pain medicine, “Sapienza” University of Rome, Rome, Italy
<b>Italo Linfante</b>	Miami Cardiac and Vascular Institute and Neuroscience Center Baptist Hospital, Miami, USA
<b>Jennifer Wong</b>	Penumbra Inc., Alameda, CA, USA
<b>John Lockhart</b>	Penumbra Inc., Alameda, CA, USA
<b>Lara Cristiano</b>	NESMOS Department, University of Rome “Sapienza”. S. Andrea Hospital, Rome, Italy
<b>Martina Novelli</b>	Department of Anestehsiology, Critical care and Pain medicine, “Sapienza” University of Rome, Rome, Italy
<b>Paolo Candelaresi</b>	Department of Emergency Medicine, San Carlo Borromeo Hospital, Milan, Italy
<b>Paolo Cerrato</b>	Stroke Unit, Department of Neuroscience, Turin University Molinette Hospital, Turin, Italy
<b>Paolo Machi</b>	CHRU Montpellier, Service de Neuroradiologie, Hopital Gui de Chauliac, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5,, Paris, France
<b>Paolo Missori</b>	Department of Neurology and Psychiatry, Neurosurgery, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy
<b>Simone Peschillo</b>	Department of Neurology and Psychiatry, Endovascular Neurosurgery/Interventional Neuroradiology, “Sapienza” University of Rome, Rome, Italy
<b>Samuele Cioni</b>	Unit of Neurointerventional, Division of Neuroradiology, Department of Neurological and Neurosensorial Sciences, University Hospital of Siena, Siena, Italy
<b>Sandra Bracco</b>	Unit of Neurointerventional, Division of Neuroradiology, Department of Neurological and Neurosensorial Sciences, University Hospital of Siena, Siena, Italy
<b>Siu Po Sit</b>	Penumbra Inc., Alameda, CA, USA
<b>Sophia S. Kuo</b>	Penumbra Inc., Alameda, CA, USA
<b>Themistoklis Papisilekas</b>	Department of Neuroradiology, Niguarda Ca’ Granda Hospital, Milan, Italy

## Epidemiology and Social Costs

Simone Peschillo<sup>1,\*</sup> and Francesco Diana<sup>2</sup>

<sup>1</sup> Department of Neurology and Psychiatry, Endovascular Neurosurgery/Interventional Neuroradiology, 'Sapienza' University of Rome, Rome, Italy

<sup>2</sup> Department of Neurology and Psychiatry, Interventional Neuroradiology, 'Sapienza' University of Rome, Rome, Italy

**Abstract:** Stroke is a pathology that has a heavy socio-economic impact, considering that the annual incidence is 15 million new cases and only one-third of these has a positive clinical outcome. Stroke is the cause of 4% of all disabilities and it does, therefore, have very high indirect social costs. The purpose of this chapter is to analyse the societal costs of stroke and compare the various treatments in order to determine which gives the best results for a contained cost.

Clinical outcome was analysed using the modified Rankin Scale (mRS), in which patients are allocated a score that depends on the presence of neurological symptoms and an impaired capacity to perform daily-life activities. The indirect costs related to reduced productivity were calculated through the analysis of various indices: disability-adjusted life years (DAYLs), years of life lost (YLL) and years lived with disability (YLD).

We calculated that a mRS score <2 obtained in 13.5% more of cases by using endovascular treatment in patients with occlusion of large vessels rather than venous fibrinolysis would lead to a saving of about 56 billion euros. Using data on the lifetime cost of a stroke, we calculated that a saving of about 11,400 billion euros could be achieved with endovascular treatment.

Clearly the savings are related to positive results that avoid indirect costs, in an ideal situation in which all patients are treated with endovascular methods. In any case, the

---

\* **Address correspondence to Simone Peschillo:** Department of Neurology and Psychiatry, Endovascular Neurosurgery/Interventional Neuroradiology, 'Sapienza' University of Rome, Rome, Italy; Tel/Fax: +390649979185; E-mail:simone.peschillo@gmail.com

analysis is a mathematical demonstration of the notable potential of this therapeutic technique.

**Keywords:** Epidemiology, Healthcare, Incidence, Mortality, Prevalence, Prevention, Risk factors, Social costs, Stroke.

## **INTRODUCTION**

Every year about 15 million people in the world suffer a stroke. Of these, 5 million die and another 5 million become severely disabled, creating an enormous financial and healthcare burden for the society and families of the patients.

In recent years improvements in diagnostic and therapeutic strategies have led to a reduction in deaths in the acute phase; however, there has been a notable increase in the incidence of ischemic strokes, particularly in developing countries, because of the more sedentary lifestyle and changes in dietary habits.

## **DEFINITION**

An ictus, also known as a cerebrovascular accident (CVA) or brain attack, is a cerebrovascular disease, usually called a “stroke”, from the original term “apoplectic stroke”, although it does not refer only to a haemorrhagic condition. This term was introduced in 1689 by William Cole and was coined from the need to classify non-traumatic cerebrovascular accidents, which had previously all been called “apoplexy”, from the time of Hippocrates in 400 B.C.

In fact, strokes include two nosological entities, ischemic accidents and haemorrhagic ones, which are extremely different with regards to aetiology, evolution and treatment. In the former case the condition is caused by a reduction or block in cerebral blood flow, which leads to cell death, whereas in the latter case, there is bleeding in the brain, with changes to the blood-brain barrier.

The currently used definition by the World Health Organization (WHO) is: *“rapidly developing clinical signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to death, with no apparent cause other than that of vascular origin.”*

Subsequently, within the ischemic accidents a further distinction was made into



strokes, which by definition are irreversible, and transient ischemic attacks (TIA), which are focal, transient events.

Interest in TIAs continues to increase and in the 1970s they were defined as “*episodes of temporary and focal dysfunction of vascular origin, which are variable in duration, commonly lasting from 2 to 15 minutes, but occasionally lasting as long as a day (24 hours). They leave no persistent neurological deficit*”. However, progresses in the field of neurology made it important to have precise definitions, rather than the arbitrary temporal limit of 24 hours, which led the American Heart Association to define a TIA as “*a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction*” (Fig. 1) [1].

*Brief notes:*

**CENTRAL NERVOUS SYSTEM (CNS) INFARCTION:** infarction of brain tissue, spinal cord or retina caused by ischemia, with symptoms that last more than 24h and have the anatomic-pathological and radiological correlates of an infarction.

**STROKE:** episode of loss of consciousness or focal motor and/or sensory neurological deficit caused by an ischemic or haemorrhagic infarction of central nervous system tissue.

**HEMORRHAGIC STROKE:** caused by blood leaking into the intracerebral or subarachnoid space.

**TRANSIENT ISCHEMIC ATTACK (TIA):** episode of loss of consciousness or focal motor and/or sensory deficit caused by ischemia, with symptoms that disappear within 24h and which do not have anatomic-pathological and radiological correlates of infarction.

## **EPIDEMIOLOGY**

Worldwide, stroke is the second cause of death and the leading cause of permanent disability, making this a problem requiring particular attention, especially considering the substantial costs to the society. These include

## Brain Ischemia and Stroke: Mechanisms and Opportunities

Francesco Orzi\* and Barbara Casolla

*Department of Neurosciences, Mental Health and Sensory Organs, University of Rome "La Sapienza", Rome, Italy*

**Abstract:** Brain function and viability strictly depend on blood flow. In case of arrest of the cerebral circulation the brain cells would survive for only a few minutes. In the perinecrotic area, where a residual blood flow is present, the brain tissue may survive for a few hours or probably days to eventually die or regain function. Both innate and adaptive immune responses, together with oxidative stress and excitotoxicity activate a damage maturation process. The interplay of the events within the neurovascular unit includes both deleterious and protective mechanisms. The complexity of the post-ischemic damage offers a number of potential therapeutic opportunities. The same complexity, however, makes it likely that each individual, potentially therapeutic, approach embraces antithetical effects, by affecting both the deleterious and protective mechanisms that drive the maturation process. The perinecrotic area seems therefore to express a heterogeneous scenario, where a patchy pattern reflects different pathologic states, depending on the intensity of the ischemic insult and on both local and systemic variables.

**Keywords:** Cerebral blood flow, Hypothermia, Metabolism, Necrosis, Neurovascular unit, Post ischemic inflammation, Programmed cell death.

### ABSOLUTE DEPENDENCE ON BLOOD FLOW

In spite of the relatively small size and weight (about 2% of the body weight) the brain takes as much as approximately  $\frac{1}{4}$  of the whole body oxygen and glucose consumption. Such a metabolic demand must be fulfilled by a supply of metabolic

---

\* Address correspondence to Francesco Orzi: Department of Neurosciences, Mental Health and Sensory Organs, University of Rome "La Sapienza", Rome, Italy; Tel: +39 0633775829; E-mail: francesco.orzi@uniroma1.it.

substrates from the blood. The supply must be continuous as the brain is without energy deposits. The average whole cerebral brain blood flow (CBF), is about 57 ml/100gr/min, in the healthy adult individual, which is about 800 ml/min, or approximately 15% of the total basal cardiac output. These data were obtained in the late 40s by means of the nitrous oxide method [1], which measures the average rates of energy metabolism and blood flow for the whole brain. The method is based on the Fick principle, which states that blood flow can be measured by assessing the concentrations of a substance within the blood as it enters and leaves the organ being supplied. The principle is an equivalent of the law of conservation of matter (Box 1).

The brain uses energy mostly for signaling-related processes. In primates, most of the energy (74%) is supposed to be consumed at postsynaptic level, for restoring the ion gradient across cell membrane. Glia may account for 5-6% of the total energy consumption [2]. Inhibitory signaling needs energy as well [3], as it depends on trans-membrane electrical potentials, which are maintained or restored by energy-dependent ion transport. The energy is obtained, under normal conditions, almost uniquely by glucose oxidation. Since the amount of oxygen stored in brain is small, the brain requires continuous supply of oxygen from systemic circulation. Glucose extraction by the brain from the blood is 10%, while oxygen extraction is 50-70%. Thus there is low extraction reserve for the oxygen. In addition there is no intracellular storage (in contrast to the muscle tissue) and an increase in blood flow is mandatory whenever there is increased energy demand. During brain activation, venous oxygen content immediately falls and blood flow must increase in order to maintain the energy supply.

However, there is no direct evidence that the hemodynamic response is consistently, or always, associated with the energy demand. Local CBF may increase as a consequence of increased signaling (mostly glutamate-, amine- or Ach-mediated). For instance, in the cerebellum activation of some pathways leads to an increase in CBF without consensual increase in metabolism [4]. Furthermore, the effects of energy consumption and neurotransmitter-related signaling may not be spatially restricted to the site of the cell firing, but the effects might be more widespread and cause an increase of CBF extended to distant areas. Such findings might be of relevance in the interpretation of the blood-

oxygen-level dependent (BOLD) contrast imaging, used in functional magnetic resonance (fMRI).

## HETEROGENEOUS ORGAN

The development of quantitative autoradiography technique allowed measurements of local tissue concentrations of chemically inert, diffusible, radioactive tracer in all the structural brain areas visible in autoradiographs of serial sections of the animal brain [5]. The autoradiography technique was applied for measuring a number of functional parameters, including local rates of CBF following infusion of tracers such as [<sup>14</sup>C] antypirine [6] and local rates of cerebral metabolism by using the [<sup>14</sup>C] labeled analog of the glucose, the 2-deoxy-D- [<sup>14</sup>C] glucose [7] (Box 1).

The exploitation of these methods in a variety of physiological conditions has definitely shown that rates of blood flow and energy metabolism are heterogeneously distributed within the brain. CBF and energy metabolism vary not only from area to area but they also vary with time, according to the dynamic changes of brain function. Under normal conditions changes in CBF and energy metabolism are concordant, and reflect local changes of functional brain activity. There are mechanisms to adjust CBF to changes in cerebral metabolic demand; there are also numerous physiological mechanisms to sustain adequate levels of blood even when arterial pressure falls (*autoregulation*). Any local increase in functional activity, under physiological conditions, is associated with local increase in CBF in order to meet the energy demand (*functional hyperemia*).

## ISCHEMIC CORE

In case of arrest of the cerebral circulation the brain cells would survive for only a few minutes. Clinicians experience the dramatic result of sudden, whole brain ischemia during a cardiac arrest. A fall in CBF to half its normal rate is sufficient to cause loss of consciousness in normal, healthy, young men. Within seconds of an ischemic insult normal brain activity ceases. Within minutes after ischemia loss of ATP results in decreased function of the ion pumps. Under a Pasteur shift of glucose metabolism caused by oxygen deprivation the pH of the ischemic tissue drops and lactic acid accumulates. Extracellular K<sup>+</sup> increases because of massive

## New Imaging Techniques

**Elena Fontana\***, Alessandro Boellis, Lara Cristiano and Alessandro Bozzao

*NESMOS Department, University of Rome "Sapienza". S. Andrea Hospital, Rome, Italy*

**Abstract:** Stroke represents an important cause of death and permanent disability in the industrialized world. Diagnostic imaging plays a key role in the clinical process, distinguishing, early in the acute phase, ischaemic stroke from primary haemorrhagic stroke. Nowadays, new imaging techniques, such as Computed Tomography Angiography (CTA), Magnetic Resonance Angiography (MRA) and perfusion imaging represents important tools in the definition of the severity of ischaemic stroke. The aim of advanced imaging techniques is to identify cerebral ischaemia within the first few hours and distinguish normal cerebral tissue from that at risk. This chapter focuses on imaging characteristics of stroke, with their anatomic-radiologic correlations, emphasizing the role of new imaging techniques, with their strengths and weaknesses.

**Keywords:** Brain infarct, Computed Tomography, Computed Tomography Angiography (CTA), CT perfusion (CTP), Ischaemic penumbra, Magnetic Resonance Angiography (MRA), Magnetic Resonance Imaging, Stroke.

### INTRODUCTION

Stroke is the third leading cause of death in industrialized countries, after ischemic heart disease and cancer, being responsible for about 10% of all deaths each year. From 15 to 30% of patients with ischemic stroke die within 30 days. Mortality within 30 days is even higher in patients with hemorrhagic stroke. Ischemic cerebrovascular disease is also a leading cause of disability, with social and economic consequences. The incidence of cerebrovascular disease increases with age, and is therefore an emerging problem, considering the aging of the

---

\* Address correspondence to Elena Fontana: NESMOS Department, University of Rome "Sapienza". S. Andrea Hospital, Rome, Italy; Tel: +39 063207903; E-mail:elena.fontana76@gmail.com.

general population; in industrialized countries stroke deaths are expected to double within 2030. [1, 2].

Stroke is defined as the sudden appearance of brain function alteration (neurological deficit), lasting more than 24 hours or resulting in death, due to an acute occlusion of an artery responsible for cerebral blood flow. Stroke diagnosis is therefore, exquisitely clinic. Anyway, diagnostic imaging plays a major role in the initial management of stroke, in the first instance being able to identify the real ischemic and non-hemorrhagic origin of the acute neurological deficit; imaging is also able to easily exclude the presence of extraparenchymal hemorrhages, tumors, abscesses and other conditions that may simulate a stroke and require different therapeutic management [3, 4].

Strokes are classified according to the triggering cause of the acute reduction of cerebral blood flow. The most common cause of ischemic stroke is an embolic vascular occlusion.

In most cases, clots originate from atherosclerotic plaques in the aortic arch or in the carotid artery (bifurcation, proximal segment or carotid siphon). Less commonly embolic occlusion can be of cardiac origin. In this case emboli originating from thrombotic material lay in the atrium, in the ventricle or in the aortic or mitral valve [4 - 6].

Less common causes of stroke, especially in Caucasians, are:

- atherosclerosis of a main intracranial vessel (most often the middle cerebral artery);
- occlusion of small intracranial arteries, often in charge of small infarcts (lacunar stroke);
- dissection of the internal carotid or vertebral artery (most common cause of stroke in younger patients);
- hemodynamic causes;
- hematologic disorders;

- vasculitis and vascular congenital anomalies [4 - 7].

## **PATHOPHYSIOLOGY**

Infarction occurs when an acute vascular occlusion cause a critical reduction of the cerebral blood flow (CBF), and cerebral perfusion is unable to meet the metabolic demands of the tissue it is supplying [8].

In normal brain tissue, a stable CBF is the most important factor for cell survival, and its value is normally of 60 mL/100g /min for the gray matter and slightly lower for white matter. Cerebral autoregulation maintains a constant CBF within a broad spectrum of systemic pressure values [8, 9]. After vascular occlusion, CBF is maintained by capillary vasodilatation of the distal microcirculation with a resultant increase in cerebral blood volume (CBV) and prolongation of the arterial transit time (MTT) [8 - 11].

Unrecoverable neuronal damage occurs when CBF falls below the critical threshold of 20 mL/100 g/min (<20% of normal), activating a sequence of pathophysiological cellular events that cause cellular energy depletion and alteration of ionic transcellular gradients.

The deregulated activation of calcium and glutamate channels causes Cytotoxic neuronal damage, peri-infarction depolarizations, cell swelling and eventually neuronal death [12 - 14].

In the affected tissue, CBF reduction is variable, depending on compensation mechanisms that are strictly related on the type of occlusion and on collateral circulation.

The central zone is defined infarction core (CBF values <20ml/100g/min), where failure of the ion pump and depolarization of the cell membrane result in shift of water from extracellular to intracellular compartments (cytotoxic edema) and inevitable cell death.

A so called “penumbral zone” (CBF between 50 and 20 ml/100g/min) of electrically inactive but viable neurons surrounds the core. Tissue within this zone may remain viable up to 48 hours after (“therapeutic window”) [10, 11, 15, 16].

---

## Medical Acute Stroke Treatment

**Paolo Candelaresi<sup>1</sup> and Alfonso Ciccone<sup>2,\*</sup>**

<sup>1</sup> Department of Emergency Medicine, San Carlo Borromeo Hospital, Milan, Italy

<sup>2</sup> Department of Neurosciences, Azienda Ospedaliera Carlo Poma, Mantua, Italy

**Abstract:** Despite the stroke burden has globally increased, particularly due to high rates of mortality and dependency in developing countries [1], advances are being made. In the last two decades, we witnessed important successes in the management of acute stroke patients, the principal of them being the development of stroke units, aspirin for the early secondary prevention, thrombolysis for the reperfusion of ischemic areas and decompressive craniectomy for malignant strokes.

This chapter will focus on the medical management of acute stroke, in particular on the thrombolytic treatment.

**Keywords:** Acute stroke, Evidence, Intra-venous thrombolysis, Ischemic stroke, Medical therapy, Neurovascular unit, Stroke unit, Systematic review, Treatment.

### INTRODUCTION

Undoubtedly, in terms of patho-physiology, the thrombolytic therapy is the most suitable treatment for acute ischemic stroke, as it targets the ischemic penumbra [2], a “functionally impaired yet still viable tissue which is characterized by the potential for recovery without morphological damage, provided that local blood flow can be re-established at a sufficient level and within a certain time window”, as it was originally defined by Astrup. In human patients, more recent imaging studies showed that the volume of irreversibly injured tissue in acute cerebral ischemia expands rapidly and relentlessly, consuming 2 million additional

---

\* Address correspondence to Alfonso Ciccone: Department of Neurosciences, Azienda Ospedaliera Carlo Poma, Mantua, Italy; E-mail: [alfonso.ciccone@aopoma.it](mailto:alfonso.ciccone@aopoma.it).



neurons per minute unless adequate reperfusion is restored [3].

### **GENERAL SUPPORTIVE CARE**

The acute phase of stroke is crucial for long-term outcome as the majority of complications arise mainly within 24 hours from onset and rarely after four days [4]. The different types of complications can be neurological (6%), infective (21%), pressure sores (21%), deep venous thrombosis (1%), pulmonary embolism (2%), pain (22%) and psychological (11%) [5]. These complications, along with cardiac complications and mortality, may be related to the quality of care provided. Intensive monitoring of vital functions such as blood pressure, pulse rate, oxygen saturation, temperature, and heart rhythm assessed by electrocardiogram (ECG), should be useful because acute medical interventions targeted at maintaining these essential physiological variables within a narrow physiological range should improve the outcome [6].

An ischemic stroke is caused by the failure of focal tissue oxygenation and energy supply, due to an arterial blood clot. Thus, it is paramount to avoid and correct those conditions which may potentially exacerbate the depletion of oxygen and glucose, such as systemic hypoxemia, hypoglycemia and hypotension, in order to limit further cellular damage.

The American Heart Association/American Stroke Association guidelines on the management of acute stroke [7] recommend “airway support and ventilatory assistance for the treatment of patients with acute stroke who have decreased consciousness or who have bulbar dysfunction that causes compromise of the airway” (Class I; Level of Evidence C). Moreover, supplemental oxygen should be provided to maintain oxygen saturation >94% (Class I; Level of Evidence C). The recent SO2S trial [8] was conducted to determine whether routine low-dose oxygen supplementation for 72 hours in patients with acute stroke and saturation levels <93% improves outcome and, further, to establish whether nocturnal oxygen supplementation is more effective than continuous oxygen supplementation. The trial failed to show any significant difference in terms of mortality or clinical outcome.

Cardiac arrhythmias that might reduce cardiac output should be corrected and

intravenous normal saline is indicated to correct hypovolemia (Class I; Level of Evidence C), at a dose of approximately 30 mL per kilogram of body weight. However, precaution is needed in patients affected by renal or heart failure, who are particularly vulnerable to intravascular volume overload.

Continuous cardiac monitoring is indicated for at least 24 hours after stroke onset in order to identify atrial fibrillation or other serious arrhythmias (Class I; Level of Evidence B).

In the acute phase of ischemic stroke, hyperthermia is associated with poor neurological outcome, as it may increase metabolic demands, enhance release of neurotransmitters, and increase free radical production. In the PAIS trial [9], treatment with high-dose paracetamol was showed to improve clinical outcome, above all in patients with a baseline body temperature of more than 36.5 °C. These findings are to be confirmed in the ongoing PAIS-2 trial. Therefore, it is recommended to identify and correct any possible source of hyperthermia (Class I; Level of Evidence C). Nevertheless, preventive antibiotic treatments only reduce the amount of infections in acute stroke patients, but do not alter the global outcome at three months, as shown by the PASS trial [10] presented at the 2014 World Stroke Conference. Whether therapeutic hypothermia is effective in acute stroke patients is being tested in the Euro-Hyp Trial.

Although stroke-related hyperglycemia is associated with greater brain injury, poorer functional outcomes, and increased mortality, intensive therapy to lower blood glucose levels does not appear to improve functional outcomes or mortality rates, as showed by a Cochrane Review [11]. It is however recommended to prevent hypoglycemia as it may cause autonomic and neurological disturbances, including stroke mimics and seizures (Class I; Level of Evidence C).

Arterial hypertension is common during an acute ischemic stroke. Both extremely high and extremely low arterial blood pressure levels are clearly detrimental, because the former carries the risk for encephalopathy, brain edema and hemorrhagic transformation, as well as cardiac and renal complications, while the latter exacerbates the ischemic damage by decreasing perfusion. Theoretically, moderate arterial hypertension during an acute ischemic stroke may improve

## Endovascular Stroke Therapy: Devices and Different Approaches

**Daniele G. Romano\***, **Samuele Cioni** and **Sandra Bracco**

*Unit of Neurointerventional, Division of Neuroradiology, Department of Neurological and Neurosensorial Sciences, University Hospital of Siena, Italy*

**Abstract:** Acute ischemic stroke (AIS) is a significant medical disease with relevant mortality and morbidity associated, that, especially in recent years, has undergone a major development of drugs and devices used for its treatment. A poor number of patients respects the criteria for treatment with intravenous drug (IVT) with recombinant tissue plasminogen activator, and the efficacy of this treatment in large vessel occlusion is percentually low. Recently, increased percentage number of patients with AIS are treated with mechanical embolectomy if IVT is ineffective or contraindicated. An important technological upgrading of devices used for the endovascular treatment of AIS, has allowed a significant increase in rates of recanalization and neurological improvement of patients treated, completely replacing the old device. Furthermore the use of these new devices has not caused an increase in intracerebral hemorrhagic (ICH). This chapter highlights the devices used in current practice for endovascular treatment of AIS, the different endovascular approaches and a brief review about the recent randomized trials, which have evaluated the efficacy of these new devices.

**Keywords:** Acute Ischemic Stroke, Endovascular treatment, Large Vessel Occlusion, Mechanical Thrombectomy, Stentrieviers, Thromboaspiration.

### INTRODUCTION

Acute ischemic stroke (AIS) is a significant medical disease with relevant

---

\* **Address correspondence to Daniele G. Romano:** Unit of Neurointerventional, Division of Neuroradiology, Department of Neurological and Neurosensorial Sciences, University Hospital of Siena, Italy; E-mail: dr.80@live.it.

mortality and morbidity associated, that, especially in recent years, has undergone a major development of drugs and devices used for treatment. Poor number of patients respects the criteria for treatment with intravenous drug (IVT) with recombinant tissue plasminogen activator, and the efficacy of this treatment in large vessel occlusion is percentually low. Recently, increased percentage of patients with AIS are treated with mechanical embolectomy if IVT is ineffective or contraindicated. An important technological upgrading of devices used for the endovascular treatment of AIS, has allowed a significant increase in rates of recanalization and neurological of the patients treated, almost completely replacing the old device.

The new devices in endovascular stroke treatment is safe, with not increase in ICH. Ischemic strokes, caused by occlusion in arterial tree of the brain, regard as for 87% of all strokes and are a leading cause of death and disability. About 7500000 people present ischemic strokes each year. The 30-day mortality in this population is 8% to 12%. In the remaining patients, the morbidity is variable, with 50% present degree of hemiparesis, 30% unable to ambulate, 19% aphasic, 35% depressed, and 26% residing in a nursing home. Only 25% of patients who survive an ischemic stroke recover fully, while the majority become disabled and a substantial proportion of these their disability is so severe that they are no longer self sufficient and need to be managed in a chronic care setting [1]. The target of treatment for AIS is to reach quickly vascular recanalization and cerebral reperfusion cerebral reperfusion before onset brain damage becomes irreversible. The relationship between early vessel recanalization and favorable modified Rankin score is known [2], although clinical factors such as age, comorbidity and stroke severity are also likely to have significant impact on clinical outcome [3]. Previously, the only FDA-approved treatment with level 1 evidence for AIS is IVT with recombinant tissue plasminogen activator (alteplase) within three hours of symptom onset [4]. Recent studies showed that expanding time window to 4.5 h a greater number of selected patients can clinical benefit [5]. Nevertheless, few patients (< 10%) meet eligibility criteria for this therapy [6].

Furthermore, the clots located into the proximal-large vessel are often resistant to IVT [7]. Early and optimal recanalization of large vessel occlusion (LVO) with IVT alone is infrequent, in approximately 10% of cases with regard to the

occlusion of internal carotid artery and 30% occlusion of the middle cerebral, and IVT is associated with increasing risk of ICH [8]. In recent years, the endovascular mechanical recanalization was developed as a safe and effective treatment. The notable technology progression of devices for mechanical thrombectomy permitted to treat an increasing number of patients with AIS when IVT is ineffective or contraindicated [9].

### **SELECTION PATIENTS FOR ENDOVASCULAR TREATMENT**

In management of acute ischemic stroke, the aim is to early identify clinical signs and thrombo-embolic occlusion of arterial tree and promptly recanalize the occluded arterial branch. Patients with hemispherical neurological stroke signs will have an occlusion of the internal carotid artery (ICA) or proximal middle cerebral artery (M1) segment in approximately 3/4 cases and will be eligible potentially for endovascular mechanical recanalization [10]. The National Institute of Health Stroke Scale Score (NIHSS) is the most important clinical tool to evaluate patients with AIS, and his high score is predictive for LVO in those patients who may be poor responders to IVT and thus better candidates for endovascular treatment.

Recent clinical trials comparing clinical outcome and revascularization rates between endovascular revascularization therapy (ERT) and intravenous thrombolysis for anterior LVO, have yielded neutral results, [11] but more clinical series reported that patients with NIHSS score  $\geq 14$  and/or proximal LVO may benefit from ERT [12]. In addition to site of arterial occlusion and NIHSS at presentation, other clinical, technical and neuroimaging factors (successful recanalization, Alberta Stroke Program Early CT Score [ASPECTS], influence stroke outcome and need to be considered during patient selection for ERT [13]. To attempt a better selection of patient, several prediction tools have been developed in clinical practice [14], but a standardized approach to patient selection for ERT is lacking across institutions [15].

Recently, some authors have established the Pittsburgh Response to Endovascular therapy score (PREs) that incorporates age, NIHSS at presentation and ASPECTS on initial head CT scan and defined this score in two large endovascular groups

## Mechanical Thrombectomy for Acute Ischemic Stroke: Review of the Evidence

**Italo Linfante\***

*Miami Cardiac and Vascular Institute and Neuroscience Center Baptist Hospital, Miami, FL, USA*

**Abstract:** Acute ischemic stroke secondary to large vessel occlusion (LVO) is a devastating condition resulting in death and disability in a high proportion of patients. Over the last 2 decades, we have witnessed a tremendous progress in the treatment of this disease. In fact, from an observational and mostly supportive care we are now in the era of acute endovascular intervention.

The first step in the right direction was the NIH/NINDS intravenous (IV) tissue plasminogen activator (tPA) trial. The trial introduced the concept of time-sensitive intervention in acute ischemic stroke. Subsequently, the endovascular approach was pioneered as treatment for this condition. However, 3 clinical randomized trials SYNTHESIS Expansion, IMS III and MR RESCUE failed to demonstrate superiority of the endovascular approach over standard IV tPA therapy. There were several drawbacks in these trials including i) not always demonstration of a LVO ii) long time to intervention and iii) most importantly, use of first generation thrombectomy devices. In fact, while these trials were ongoing, retrievable stents in SWIFT and TREVO 1 and 2 showed to be superior to first generation thrombectomy devices.

Using latest generation technology, MR CLEAN, ESCAPE, EXTEND IA, SWIFT-PRIME and REVASCAT, 5 multicenter, controlled, randomized, clinical trials showed overwhelming superiority of the endovascular approach over medical management for acute LVO.

**Keywords:** Ischemic stroke, Randomized clinical trials, SOLITAIRE stent retriever, Thrombectomy.

---

\* **Address correspondence to Italo Linfante:** Miami Cardiac and Vascular Institute and Neuroscience Center Baptist Hospital, Miami, FL, USA; Tel: (786) 596-5990; Fax: (786) 596-2999; E-mail: italol@baptisthealth.net

## **INTRODUCTION**

There has been a tremendous progress in the treatment of ischemic stroke secondary to large vessel occlusion (LVO). Recently, level 1A evidence was generated by multicenter, controlled, randomized clinical trials. These clinical trials showed that we now a treatment that can result in a life without disability for acute ischemic stroke patients.

The purpose of this chapter is review the development of endovascular stroke therapy though the analysis of the evidence presented in randomized clinical trials.

The first step in treating acute ischemic stroke successfully is the notion that early reperfusion of a large vessel occlusion (LVO) can produce dramatic improvement in the patient's symptoms [1]. Exactly 20 years ago, the National Institute of Neurological Disorders and Stroke (NINDS) investigators showed superiority of recombinant IV tissue plasminogen activator (r-tPA) *versus* placebo in acute ischemic stroke [1]. The data came on the shoulder of three well-performed but negative trials [2 - 4]. Undoubtedly, the NINDS IV tPA trial established once and for all the concept of acute, time-dependent reperfusion therapy in cerebral ischemia. At that time, it was an historical step forward. In fact, until then the approach to patients with acute ischemic stroke consisted of supportive care, rehabilitation, and secondary stroke prevention.

As IV tPA was being used world-wide, it was reported that it may result in low rates complete recanalization in LVO. This was particularly true for proximal occlusions [5]. Endovascular recanalization therapy was then the most logical development on the road to treat LVO successfully.

The initial attempt to endovascular therapy of acute ischemic stroke was based on intra-arterial thrombolysis and then first generation mechanical thrombectomy devices (*i.e.* Concentric Thrombus Retriever and Penumbra device) [6, 7]. The clinical utility of this approach was tested in 3 randomized clinical trials: 1) SYNTHESIS-Expansion 2) IMS III and 3) MR RESCUE. The trials were presented and concurrently published in *The New England Journal of Medicine* in 2013 [8 - 10].

## **SYNTHESIS-EXPANSION**

Ciccone *et al.* deserve credit for being able to design and execute a multicenter randomized clinical trial of endovascular therapy that reflected the standard of care at that time [8]. In particular, the investigators selected and randomized 362 patients with acute ischemic stroke treated within 4.5 hours after symptom onset. The patients were randomized to IA thrombolysis with rtPA, mechanical thrombectomy (*i.e.* wire manipulation or Concentric Thrombus Retriever) or a combination of all. The trial did not mandate a diagnosis of LVO or time constraints for treatment. According to the trial design patients were treated “as soon as possible after randomization”.

As primary outcome, SYNTHESIS-Expansion decided to use free of disability survival as assessed by a modified Rankin score (mRS) of 0 or 1 at 3 months.

In the trial, 181 patients were randomized to endovascular therapy while 181 were treated with 0.9 mg/Kg of IV rtPA. There was a significant delay in the time from stroke onset to treatment between endovascular therapy (3.75 hours) and IV rTPA (2.75 hours) ( $P < 0.001$ ). The trial missed the primary outcome for endovascular therapy. In fact only 55 patients (30.4%) had a mRS  $\leq 1$  in the endovascular arm *versus* 63 (34.8%) in IV rt-PA group. The difference was not statistically significant.

With regards to safety also there was no difference between the two treatments. In fact, symptomatic intracranial hemorrhage was present in 6% of the patients in each group. The investigator concluded that endovascular therapy as performed in the trial, was not superior to standard medical management with 0.9 mg/Kg of IV rtPA.

## **Interventional Management of Stroke (IMS III)**

The Interventional Management of Stroke (IMS III) trial was a National Institute of Health (NIH) sponsored, multicenter, randomized clinical trial to evaluate if endovascular stroke therapy was superior to IV rTPA in patients eligible for IV tPA [9]. In particular, eligible subjects for the trials were patients who received IV tPA within 3 hours after symptom onset and were randomized to endovascular



## Neurosurgery in Brain Ischemic Stroke

**Paolo Missori\*** and **Cristina Mancarella**

*Department of Neurology and Psychiatry, Neurosurgery, Policlinico Umberto I, "Sapienza" University of Rome, Italy*

**Abstract:** Ischemic strokes caused by the complete occlusion of an intracranial artery are associated with poor outcomes overall, and high mortality rates. To improve the survival and the outcome otherwise not afforded by the available medical and interventional therapies a neurosurgical approach must be considered. In selected patients a microsurgical embolectomy and a decompressive craniectomy are effective therapies with which to treat occlusions of the middle cerebral artery or other territories when thrombolysis or an interventional endovascular embolectomy does not restore the vascular flow. A bypass procedure that employs a superficial temporal artery-to-middle cerebral artery (STA-to-MCA) surgical anastomosis can be performed to improve the blood flow in a deficient artery chronic angiopathic disorder.

**Keywords:** Bypass, Decompressive craniectomy, Encephalo-myo-synangiosis, Ischemia, Intracranial pressure, Microsurgical embolectomy, Middle cerebral artery, Neurosurgery, Stroke.

### INTRODUCTION

Strokes are predominantly ischemic (up to 90%) rather than hemorrhagic events [1, 2]. In a 20-year comparative study, mortality from hemorrhagic stroke appeared to decrease significantly (nearly 50%), while the mortality rate associated with ischemic stroke in young adults decreased by only 15% [3]. When untreated, strokes caused by the occlusion of anterior circulation in the proximal intracranial artery are associated with poor outcomes overall, with mortality for

---

\* **Address correspondence to Paolo Missori:** Department of Neurology and Psychiatry, Neurosurgery, Policlinico Umberto I, "Sapienza" University of Rome, Italy; E-mail: missorp@yahoo.com; cristina.mancarella@gmail.com

ischemic stroke averaging 50% [4, 5]. A dismal prognosis is expected in when occlusion of the middle cerebral artery territory is complete, because space-occupying edema and concurrent brain herniation develop during the initial 5 days after presentation [6]. When more than 50% of the middle cerebral artery territory is involved, fatal brain swelling occurs [7, 8]. In the neurosurgical management of selected patients with ischemic stroke, there is an expanding role to improve the survival and the outcome otherwise not afforded by the available medical and interventional therapies.

### **Microsurgical Embolectomy**

Patients with complete occlusion of the middle cerebral artery territory from an embolic specimen are eligible for thrombolytics within 4.5 hours of the onset of symptoms [9]. In those patients in which thrombolysis does not restore the vascular flow, an interventional endovascular embolectomy with a retriever device may be considered within 8 hours of symptom onset [10, 11]. When neither of these procedures is appropriate or neither resolves the occlusion, the possibility of an emergency microsurgical embolectomy (ME) should be evaluated in selected patients [12 - 17]. The first attempt to surgically remove embolic tissue from the middle cerebral artery dates back to 1956, when Keasley Welch (1920-1996) performed the procedure in two young adult patients [18]. ME data from magnetic resonance angiography (MRA)/diffusion-weighted imaging (DWI) mismatch indicate that a short median recanalization time (the interval between symptom onset and emergent surgery) appears to produce a high rate of complete recanalization and a low complication rate [15, 16]. The initial reports and series that described patients undergoing ME were in young adult patients [19 - 23]. More recently, single reports or case series of patients show that the majority are older (mean age 77-80 years), probably the effect of ME being employed as a second-tier treatment in these patients after other treatments have failed [12, 15, 16, 24, 25].

The microsurgical technique requires experienced hands [14]. The first step is the choice of a surgical approach that provides very fast access to the thrombosed artery during the short window in which ischemic stroke can be managed. For this reason, each neurosurgeon performs the surgery in accordance with their personal

skill and the location of the occluded vessel: pterional, frontotemporal, laterally extended superciliary, and anterior temporal approaches have been reported [13, 14, 26, 27, 28].

In case of middle cerebral artery occlusion, the arachnoid of the Sylvian fissure must be opened using the usual microsurgical technique. The small perforating branches that frequently originate from the insular segment of the middle cerebral artery (M2) are detected and carefully protected to avoid any injury from either traction or pressure. The distal portion of the occluded artery is exposed. A temporary vascular clip is placed proximal to the presumed vascular occlusion; a distal vascular clip may also be advisable in some cases to avoid the embolization of small fragments from a brittle clot in the distal patent artery. A longitudinal or transverse microarteriotomy (3 mm length) allows opening of the wall of the occluded vessel and removal of the clot through suction or gentle squeezing of the artery. Transient opening of the proximal vascular clip enables the blood flow to clean all residual clot fragments from the occluded branch and assures complete restoration of blood flow. In some cases, multiple arteriotomies may be required to remove a long embolus [27]. Intermittent sutures, vascular closure staples, or microclips are applied, and recanalization is confirmed by micro-Doppler ultrasound or indocyanine green angiography [26, 28, 29, 30].

Complications from the surgical procedure are those common to any intracranial neurosurgical approach, and are relatively rare. In 4% to 8% of patients treated with ME, on average, restoration of blood flow has reportedly changed an infarct into a hemorrhagic lesion (reperfusion injury) [15, 24, 26]. Treating the patient within a short interval appears to avoid such events, probably because the ischemic stroke is not complete or because the involved brain tissue is still viable [14, 16, 17, 27]. Indeed, collateral flow, which varies widely among individuals, is considered the best predictor of outcome [31 - 35]. The results of surgical embolectomy exhibit a high rate of complete recanalization, with 70% to 100% improvement of the National Institutes of Health Stroke Scale (NIHSS) score at 1 month after the event [15, 16]. Future series must better define the role of surgical embolectomy as an effective therapy with which to treat occlusions of the middle cerebral artery or other territories, to be considered at least in selected patients independent of other therapies.

---

## Clinical, Pharmacological and Endovascular Management of Cerebral Venous Thrombosis

Federico Di Maria<sup>1,\*</sup>, Flore Baronnet-Chauvet<sup>2</sup>, Charlotte Rosso<sup>2,3</sup> and Frederic Clarençon<sup>1,3</sup>

<sup>1</sup> APHP, Service de Neuroradiologie Interventionnelle Groupe Hospitalier Pitié Salpêtrière, 75013, Paris, France

<sup>2</sup> APHP, Urgences Cérébro-Vasculaires, Groupe Hospitalier Pitié-Salpêtrière, 75013, Paris, France

<sup>3</sup> Faculté de Médecine, Université Paris 6 “Pierre et Marie Curie” (UPMC) 75005 Paris, France

**Abstract:** Cerebral venous thrombosis is a quite infrequent condition (3-4 per million) that affects predominantly young patients. It is typically characterized by a variable clinical spectrum and prognosis is influenced by several factors. Diagnosis is sometimes difficult since symptomatology is often non-specific. Imaging work-up by CT and MRI plays an important role in patient triage and diagnosis. Modern modalities allow an excellent visualization of the venous system and a precise identification of the intra-luminal thrombus. Imaging may also add an interesting prognostic value. Medical management mainly consists in anticoagulation, reduction of intracranial hypertension and treatment of underlying triggering conditions. In recent years, endovascular techniques have emerged as a new interesting option in patients poorly responding to medical therapy, with promising results. In this chapter, we sought to review the current knowledge on the clinical management, imaging diagnosis, medical and endovascular treatment of this pathology.

**Keywords:** Anticoagulation, Cerebral venous thrombosis, Complications, CT, Diagnosis, Dural sinus, Endovascular treatment, Imaging, MRI, Symptoms, Thrombectomy, Thromboaspiration.

---

\* Address correspondence to Federico Di Maria: APHP, Service de Neuroradiologie Interventionnelle Groupe Hospitalier Pitié Salpêtrière, 75013, Paris, France; Tel: 0033 1 42163599; E-mail: Federico.dimaria@gmail.com

Simone Peschillo (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

## **INTRODUCTION**

Cerebral venous thrombosis (CVT) remains an often underdiagnosed pathology, being a relatively uncommon disease characterized by a wide spectrum of etiologies, clinical presentation, and variable prognosis. The purpose of this work is to review current knowledge about CVT concerning its clinical manifestations, diagnosis, and treatment, with particular focus on imaging modalities and endovascular treatment approaches.

### **Clinical Presentation**

Onset of symptoms may be acute, subacute or even chronic. Even if clinical presentation of cerebral venous thrombosis can be highly variable, there are four described major clinical patterns which may appear either isolated or in different combinations:

- Isolated intracranial hypertension: headache is the most frequent symptom, present in nearly 90% of patients. It can be accompanied by papilledema, with or without visual loss. Sixth nerve palsy can also be observed. When those symptoms are isolated (up to 25% of patients), the diagnosis of CVT can be particularly difficult, the more so as the value of D-dimer is normal in 25% of the cases [1, 2].
- Focal deficit, including hemiparesis, hemiparesthesia or aphasia, are noted in 44% of patients [3] and are most often related to the presence of venous infarction.
- Focal or generalised seizures are presents in 30% to 40% of patients, mostly in case of thrombosis of the sagittal sinus or cortical veins [3].
- Encephalopathy can be observed in thrombosis of the straight sinus or in case of extensive thrombosis with severe cerebral edema [2].

The ISCVT cohort [4] illustrates the variability of symptoms onset: acute (<48h) in 37% of patients, subacute (>48h to 30 days) in 56% of patients, or even chronic (> 30days) in 7% of patients.

### **Risk Factors and Clinical Work-up**

Causes of CVT are multiple and cause-effect relationship is sometimes difficult to

establish, except for severe admitted thrombophilia. General systematic work-up up must be completed for each patient.

The largest study, the ISCVT, is a multicenter, prospective observational study with 624 patients [4]. In this study, thirty-four percent of these patients were harboring a prothrombotic condition. However, no cause of CST was found in about 15 % of cases, although an underlying disease may be detected in these patients may detect up to several months later [4]. It is recommended in these cases to perform again the assessment of thrombophilia at the end of the anticoagulation treatment.

**Table 1. Summarizes the different risk factors and the subsequent patient work-up.**

(Table 1) cont.....

Risk Factors		Work-up
Thrombophilia	Antithrombin III, protein C and S deficiencies  Antiphospholipid and anticardiolipin antibodies  Factor V Leiden gene mutation and Resistance to activated protein C  Prothrombin G20210 mutation (factor II)  Hyperhomocysteinemia and MTHFR gene mutation	Standard blood cells and platelet count, BT, PT, APTT, fibrinogen  Blood level of antithrombin III, protein C and S, homocysteinemia  Genetic analysis of Factor V gene, prothrombin gene and MTHFR gene.  Measure of the resistance of activated protein C
Women risk factor	Pregnancy and puerperium  Oral contraceptives	Anamnesis
Local and systemic infections	Sinus, teeth, ear  Meningitis	CT of sinuses, dental panoramic X-Ray  Lumbar puncture

## Intracranial Stenosis: Medical and Endovascular Management

Alessandro Stecco<sup>1</sup> and Paolo Machi<sup>2,\*</sup>

<sup>1</sup> *Neuroradiology Unit, Radiology Dept, Novara Maggiore Hospital, Italy*

<sup>2</sup> *CHRU Montpellier, Service de Neuroradiologie, Hopital Gui de Chauliac, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France*

**Abstract:** Intra-Cranial Arterial Stenosis (ICAS) represents a source of risk to develop stroke. There is some genetic and ethnic determinant in having a major risk. Non invasive diagnosis rely on Trans-Cranial Doppler (TCD) and Magnetic Resonance Angiography, while Computed Tomography has the best accuracy to be compared to the more invasive Digital Subtraction Angiography. The endovascular and medical therapy options are compared, passing through WASID and SAMMPRIS trials.

**Keywords:** Angiography, Arterial, ASA, CT, Measurement, MRA, Risk factors, Stenosis, Stroke.

### INTRODUCTION

Intracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke in the world [1]<sup>1</sup>.


### NEUROIMAGING OF ICAS

Imaging characteristics affect both the risk of recurrent events and the clinical outcome of a patient with ICAS, undergoing to a stroke event [16]. The degree of the stenosis and the collateral circulation status [27 - 28] are two main factors

---

\* **Address correspondence to Paolo Machi:** CHRU Montpellier, Service de Neuroradiologie, Hopital Gui de Chauliac, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France; E-mail: paolo.machi@gmail.com.

influencing the cerebral hemodynamic and the clinical outcome of a ICAS . About the degree of the stenosis, stenosis > 70% of the vessel, affect differently the outcome than stenosis ranging 50-69% [29], while robust antegrade flow and good collaterals are protective factors toward stroke also in presence of a ICAS (Fig. 1).



**Fig. (1).** A-F: Left Acute Hemiparesis in 50yrs smoker female. **A) mild subcortical right frontal hypodense area at not-enhanced CT (NECT); B-C) CT Angiography elaborated with MIP algorithms at 5 mm of thickness, in coronal oblique and axial planes, showing the severe steno-occlusion of the right Middle Cerebral Artery; D) 48 hrs follow-up NECT showing evidence of the ischemic area; E) Diffusion Weighted Imaging (DWI) showing the white matter ischemia along the right corona radiata, less than expected in presence of a severe MCA steno-occlusion; F) the first CTA reformatted with large MIP sections to see the quality of collaterals, shows a pattern of good collaterals.**



The pattern of ischemic lesions in Magnetic Resonance with Diffusion Weighted Imaging (DWI) can predict the recurrency of ischemic lesions in symptomatic patients with ICAS; subcortical or multiple lesions indicate a more severe stenosis and predict a recurrent stroke [30].

The trial called SONIA (Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis) trial assessed the accuracy of Trans Cranial Doppler (TCD) and Magnetic Resonance Angiography (MRA) compared with catheter cerebral angiography [31] TCD and MRA yielded high negative predictive values (NPV) (86–91%) but low positive predictive values (36–59%). In this study, in TCD examinations, the middle cerebral artery and basilar/vertebral Mean Flow Velocity (MFV) were recorded placing cursors on peak systolic and end diastolic velocity values: for the first artery the cut off for identification of stenosis  $\geq 50\%$  was a MFV of  $\geq 100$  cm/s, for the basilar/vertebral was of 80 cm/s.

A high NPV allow to consider a test as screening for exclusion of intracranial arterial stenosis, while the low PPV isn't enough to considered it for correct diagnosis and accurate estimation of the severity of stenosis.

The detection of stenosis of intracranial vessels as Middle Cerebral Artery (MCA), is best accomplished by not-invasive diagnostic methods as TCD, for screening, and/or MRA both for screening or confirmation.

CTA is more accurate and with more sensitivity and specificity than MRA for the diagnosis and characterization in 50% or higher ICAS [32, 33].

CTA radiation exposure burden, make actually acceptable to firstly perform a MRA with 3D Time of Flight Technique, unless in an emergency condition.

MRA, better if in high resolution (3 Tesla) settings, and subject to further technological improvement, can allow a sensitivity of 78% - 85% and specificity of 95% in detecting a  $>50\%$  stenosis, and 100% and 99% for the detection of complete occlusion [34]. This method is affected by flow void artifacts due to dephasing of the blood spins in very narrow vessels lumina, and by post-processing artifacts [35]. For this reason a congenital narrower lumen or an asymmetrical presentation between the two sides, can falsely be interpreted as an

---

## Uncommon Cause of Stroke: Diagnosis and Treatment (Part I)

Paolo Cerrato<sup>1,\*</sup>, Alessandro Pezzini<sup>2</sup> and Giovanna Vaula<sup>3</sup>

<sup>1</sup> Stroke Unit, Department of Neuroscience, Turin University Molinette Hospital, Turin, Italy

<sup>2</sup> Department of Clinical Science, Neurological Clinical Brescia University, Italy

<sup>3</sup> Stroke Unit, Department of Neuroscience, Turin University Molinette Hospital, Turin, Italy

**Abstract:** This chapter contains detailed, up-to-date information about the nature, diagnosis, and treatment of those relatively uncommon types of cerebrovascular disease that cause strokes. Although many of the conditions discussed are rare, the chapter covers the causes of up to 10% to 15% of all strokes and of up to 40% of strokes in young adults. This chapter may be an essential resource to help physicians diagnose and treat stroke patients who do not fit well into the usual clinical categories.

Discussed within are the dissection of carotid and vertebral arteries, the more relevant cause of stroke in the young. The collagen vascular disorders causing stroke as a consequence of dissection, occlusion and, more rarely, rupture of extracranial and intracranial arteries are reported in detail. Various forms of cerebral angiitis, with focus on the primary central system vasculitis and reversible cerebral vasoconstriction syndrome are discussed.

**Keywords:** Cerebral infarction, Cerebral small vessel diseases, Cerebral vasculitis, Collagen vascular disorders, Genetic disorder, Metabolic disorders, Stroke.

---

\* Address correspondence to Paolo Cerrato: Stroke Unit, Department of Neuroscience, Turin University Molinette Hospital, Turin, Italy; Tel: 00390116334985; E-mail: paolo\_cerrato@yahoo.com.

## **COLLAGEN VASCULAR DISORDERS AND OTHER NON INFLAMMATORY VASCULOPATHIES**

Numerous non inflammatory vascular pathologies may cause stroke either ischemic or hemorrhagic. These include fibromuscular dysplasia, some genetically defined collagen vascular disorders (Marfan syndrome, Ehler- Danlos syndrome, osteo-genesis imperfecta, neurofibromatosis, pseudoxantoma elasticum and polycystic kidney disease) and other uncommon disorders such as Sneddon syndrome and Moya-moya syndrome.

### **FIBROMUSCULAR DYSPLASIA**

Fibromuscular dysplasia (FMD) is nonatherosclerotic, noninflammatory arterial disorder that may result in arterial stenosis, occlusion, aneurysm, or dissection [1 - 4]. FMD has been reported in various arterial bed but most frequently affects the renal (causing hypertension) and extracranial carotid and vertebral arteries [5]. The natural history of cerebrovascular FMD is generally benign and the mean age of patients with cerebrovascular FMD is approximately 50 years [4].


Genetic studies have the potential to advance our understanding of FMD but no etiologic genes for FMD have been identified nowadays. Various classification of FMD have been proposed [5,6] the most recent being the AHA classification (Table 1).

According with Harrison and McCormack [6] the classification system categorized FMD in relation to the arterial layer involved, namely intimal, medial, and adventitial disease (Table 1). Angiographic correlations have been derived largely from the work of Kincaid and colleagues [7]. The medial FMD account of the majority of the cases and include three subtypes: the medial fibroplasia (60%–70%), the perimedial fibroplasia (15%–25%) and the medial hyperplasia (5%–15%). The most common features were multiple areas of stenosis and dilatation (string of beads) or focal and tubular stenosis (Figs. 1 - 3).

The 2012 French and Belgian consensus statement [2] supported a radiographic classification, with multifocal, unifocal (<1 cm stenosis), and tubular (≥1 cm) subtype (Table 1). It was further proposed by American Heart Association

classification [5] that the unifocal and tubular be combined into 1 definition of unifocal.

According to the Harrison’s hypothesis [6] multifocal FMD is the subtype with string of beads appearance mostly due to medial fibroplasia. Focal FMD regardless of lesion length, is usually caused by intimal fibroplasia, but may also be caused by medial hyperplasia or adventitial FMD. Indeed, focal and multifocal FMD are not the same disease.



**Fig. (1).** Images of a patients with fibromuscular dysplasia. Cerebral angiography shows a “string of beads pattern” (arrow) at the level of extracranial internal carotid artery (A), as well as at the level of the V3 segment of vertebral artery (B, thin arrows).

**Table 1. Classification of fibromuscular dysplasia.**

Histological		Angiographic	
<i>Harrison and McCormack (1971)</i>		<i>French/Belgian Consensus (2012)</i>	<i>American Heart Association (2014)</i>
● Medial		● Multifocal	● Multifocal
	Medial fibroplasia (60-70%)		
	Perimedial fibroplasia (15-25%)		
	Medial hyperplasia (5-15%)		
● Intimal fibroplasia (1-2%)		● Unifocal (<1cm)	● Focal*
● Adventitial (<1%)		● Tubular (>1cm)	

\*There may be multiple areas of focal disease (e.g. Renal artery and carotid artery in the same patient). Focal and multifocal disease can occur in the same patient.

## Uncommon Cause of Stroke: Diagnosis and Treatment (Part II)

Paolo Cerrato<sup>1,\*</sup>, Alessandro Pezzini<sup>2</sup> and Giovanna Vaula<sup>3</sup>

<sup>1</sup> Stroke Unit, Department of Neuroscience, Turin University Molinette Hospital, Turin, Italy

<sup>2</sup> Department of Clinical Science, Neurological Clinical Brescia University, Italy

<sup>3</sup> Stroke Unit, Department of Neuroscience, Turin University Molinette Hospital, Turin, Italy

**Abstract:** This chapter contains detailed, up-to-date information about the nature, diagnosis, and treatment of those relatively uncommon types of cerebrovascular disease that cause strokes. Although many of the conditions discussed are rare, the chapter covers the causes of up to 10% to 15% of all strokes and of up to 40% of strokes in young adults. This chapter may be an essential resource to help physicians diagnose and treat stroke patients who do not fit well into the usual clinical categories.

Discussed in this chapter are the various form of inherited small vessel disease such as CADASIL but even the less known Col 4A1/2 related syndromes, CARASIL, TREX1-gene mutations disorders and the cerebretinal microangiopathy with calcifications and cysts. Three form of metabolic disorders causing stroke such as Fabry disease, Homocystinuria and MELAS as well as the most relevant form of hematological disorders (antifosfolipid syndrome and sickle cell disease) are discussed. Finally intriguing disorders such as migrainous infarction and drugs related stroke disorders are detailed as well as some other rare disease such as Kohlmeier–Degos disease and acute posterior multifocal placoid pigment epiteliopathy.

**Keywords:** Antifosfolipid syndrome, Cerebral infarction, Cerebral small vessel diseases, Drugs, Genetic disorder, Metabolic disorders, Sickle cell disease, Stroke.

---

\* Address correspondence to Paolo Cerrato: Stroke Unit, Department of Neuroscience, Turin University Molinette Hospital, Turin, Italy; E-mail: paolo\_cerrato@yahoo.com

## **HEREDITARY CEREBRAL SMALL VESSELS DISEASES**

The existence of familial small vessel disease was supposed since the description of Van Bogaert in 1955, of two sisters affected by a rapidly evolving Biswanger disease. It is however only in 1993 that the first genetic small vessel disorder (CADASIL) was mapped on chromosome 19.

Since then several other monogenic disorders involving cerebral small vessels have been clinically and genetically characterized, the common features of which being represented by early onset of subcortical or lacunar strokes, leukoencephalopathy and involvement of small penetrating arterioles [1].

This chapter will focus on cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Collagen 4A1 and 4A2 (COL4A1/A2) related disorders and the rarer cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and TREX1 related diseases.

Small vessel involvement is also present in hereditary cerebral amyloid angiopathies and it is described, in association with large vessel pathology, in several other monogenic diseases such as Fabry disease, pseudoxanthoma elasticum and homocystinuria. These disorders are detailed elsewhere.

Moreover several families are reported with a CADASIL like MRI phenotype, in which the genetic defects is currently unknown: it is the case of the hereditary multi infarction dementia of the Swedish type [2], the pontine autosomal dominant microangiopathy and leukoencephalopathy (PADMAL) [3]. Finally cerebral microangiopathy is a feature of Coats plus syndrome (actually renamed as cerebroretinal microangiopathy with calcifications and cysts – CRMCC).

### **CADASIL**

CADASIL is the first hereditary small vessel disease to be genetically defined [4]. The disease was identified more than 30 years ago, but the term CADASIL emerged in 1993 when the disease causing gene was first mapped on chromosome 19p13.1 and then identified as NOTCH3, three years later.

Since then CADASIL has been reported worldwide and although its prevalence is not known, it has been estimated approximately 5/100.000, based on studies from United Kingdom [5] CADASIL represents a non-arteriosclerotic, non-amyloid arteriopathy affecting the small perforating cerebral arteries whose pathological hallmarks are the accumulation of granular, osmiophilic material within the tunica media, the degeneration of vascular smooth muscle cell and the intimal thickening. These processes result in stenosis of the distal segment of medullary arteries and in loss of the autoregulation mechanisms of the cerebral vessels

### **PATHOGENESIS**

The disease is caused by mutations in NOTCH3 gene that encodes a transmembrane receptor protein with 3 functional domains: an extracellular domain that is formed by 34 epidermal growth factors repeats (EGFR) and 3 Notch/lin repeats; a transmembrane domain and an intracellular domain. Notch3 receptor exists at the plasma membrane as a heterodimer and is predominantly expressed in vascular smooth muscle cells of small arteries and pericytes of brain capillaries.

In response to ligand binding, the receptor undergoes sequential proteolytic cleavages that release the Notch intracellular domain, which in turn translocates to the nucleus, binds to specific transcription factors and promote the transcription of genes.

CADASIL mutations occur in exon 2-24 and are usually missense mutations: in frame deletions and splice site mutations are rarer.

The vast majority of the mutations affect the EGFR extracellular domain and results in the gain or loss of a cysteine residue leaving an unpaired sulphidril group that can promote multimerization and aggregation of mutant Notch 3 receptor. There are increasing reports of cysteine sparing mutations and their role is still controversial, representing either rare single-nucleotide polymorphisms or CADASIL or other than CADASIL small vessel disease causing mutations. At least for several of these mutations, the ability to form Notch3 aggregates has been demonstrated [6].

## Endovascular Management of Atherosclerotic and Dissected Carotids

**Guglielmo Pero\*** and **Themistoklis Papasilekas**

*Department of Neuroradiology, Niguarda Ca' Granda Hospital, Milan, Italy*

**Abstract:** Treatment of lesions of the extracranial internal carotid artery plays an important role in the management of ischemic stroke, particularly in the secondary prevention of further events, but sometimes also in the acute phase. The endovascular management of atherosclerotic stenosis is not just an alternative to endarterectomy but frequently is the treatment of choice. Moreover, treatment of dissections of the carotid arteries, when not exclusively medical, is in almost all cases endovascular. Experience in the neurointerventional field is necessary to correctly deal with both types of lesions of the extracranial internal carotid artery.

**Keywords:** Carotid stenting, Carotid dissection, Carotid atherosclerosis, Atherosclerotic plaque, Carotid stenosis, Endovascular treatment.

### INTRODUCTION

Atherosclerotic stenosis of the extracranial internal carotid artery (ICA) is a frequent cause of stroke [1, 2]. Discovered usually only after the patient has already suffered an ischaemic event, it is nowadays clear that symptomatic carotid stenosis requires treatment. The first evidence towards this came in 1998 from two large randomized trials, the North American Symptomatic Carotid Endarterectomy Trial (NASCET) [3] and the European Carotid Surgery Trial (ECST) [4]. These studies compared endarterectomy for symptomatic stenosis to conservative management (antiplatelets), both demonstrating the superiority of

---

\* Address correspondence to **Guglielmo Pero**: Department of Neuroradiology, Niguarda Ca' Granda Hospital, Milan, Italy; E-mail: pergulli@me.com.



surgery in preventing new ischaemic events and death. Notably, later trials have also provided evidence in favour of surgically treating severe carotid stenosis even in asymptomatic patients, the benefit though is, in these cases, less pronounced [5, 6].

During the past couple of decades, minimally invasive therapies have been continuously gaining ground in the field of vascular diseases. In this context, carotid stenting was originally introduced as an alternative to endarterectomy for the elderly and high surgical risk patients. Although good results have been reported by several case series published in the literature [7 - 10], it has not been till recently that randomized trials were put into place to address the issue. Notably, most of these trials have failed to demonstrate any significant difference both in efficacy and safety between the two techniques [11, 12]. Studies that showed stenting associated with a higher risk profile have been largely disregarded as their results have been attributed to the limited experience of the centres involved rather than the technique itself [13, 14]. Furthermore, surgical complications such as cranial neuropathies, wound haematoma and infection have been underrated in most published studies and this is something that one should keep in mind when doing any comparisons.

Despite considerable debate in the past, current guidelines advocate that best medical treatment should be generally preferred over surgery/stenting in asymptomatic patients (there are selected cases though that non-conservative treatment may still be useful) [15].

The endovascular technique of carotid stenting is, in itself, relatively easy but it requires experience in patient selection, correct choice of devices and, mainly, appropriate management of possible adverse events.

The current chapter will focus on endovascular techniques applicable to carotid disease, either atherosclerotic stenosis or dissection. Carotid stenting, although rather straightforward in concept, requires careful choice of devices and appropriate perioperative management. Adverse events, even if rare, can prove devastating for the patient and should be thus readily recognized and treated.

## **INDICATIONS OF CAROTID STENTING**

As previously stated, the NASCET and ECST trials showed, back in 1998, that symptomatic severe carotid stenosis benefits from surgical treatment [3, 4]. Most of the succeeding trials comparing standard endarterectomy to endovascular stenting found the former to be non-significantly better both in terms of safety (periprocedural stroke and death in the 30 days succeeding the treatment) and efficacy (the rate of stroke and death between 31 days and 6 months after the procedure) [11, 12]. However, further analysis revealed that there is still a place for stenting in specific patient sub-groups [11].

An in-depth analysis of all the randomized trials that have compared surgical and endovascular treatment of carotid disease is probably out of context here. Several authors have extensively reviewed the subject [11, 12, 15, 16] and identified critical factors that should be taken into consideration when choosing between surgical or endovascular treatment of carotid stenosis:

### **Patient Related Factors**

- Age
- Surgical risk
- Comorbidities

### **Anatomy Related Factors**

- Location of the carotid bifurcation
- Aortic arch conformation
- Tortuosity of the vessels
- Stability of the plaque

Contra intuitively, and despite previous beliefs, clinical trials have shown by now that elderly patients do not benefit from stenting [11], probably because of the higher atherosclerotic burden on their vessels and especially in the aortic arch. Navigation through such vessels (like in ultra-octogenarian) increases the risk of embolic complications due to plaque fragmentation. Of note is that in the CREST study, the crossover between endarterectomy and stenting occurred at approximately 70 year [17, 18].

---

## Intensive Care Management

**Federico Bilotta<sup>\*</sup>, Martina Novelli, Filippo Pecorari and Giovanni Rosa**

*Department of Anesthesiology, Critical Care and Pain Medicine, "Sapienza" University of Rome, Rome, Italy*

**Abstract:** Acute ischemic stroke represents a leading cause of mortality and morbidity worldwide. An increasing number of patients with massive stroke require admission to ICU for neurological monitoring and management of acute complications. Medical treatment in ICU consists of sedation, analgesia, ventilator support, hemodynamic monitoring, neuromonitoring, fluid management, thromboprophylaxis and treatment of complications. Principal complications are: cerebral edema, hemorrhage, seizures, myocardial complications, hyperglycemia and fever. Severe cerebral edema after stroke represents an important complication. In this case, decompressive craniectomy successfully decreases mortality and morbidity in patients with severe cerebral edema. Therapy with mannitol is the standard treatment for intracranial hypertension. Therapeutic hypothermia may also be considered for its neuroprotective effect but its role is not demonstrated in stroke. These aspects of critical care are considered in this chapter.

**Keywords:** Acute ischemic stroke, Cerebral edema, Intensive care management, Intracranial hypertension, Neurocritical care, Neuromonitoring, Reperfusion therapy, Stroke units.

### INTRODUCTION

Acute ischemic stroke (AIS) is an important cause of morbidity and mortality in the world. Despite around 15-20 % of stroke patient being admitted to the intensive care units (ICU), the evidence base guiding the intensivist managing

---

<sup>\*</sup> **Address correspondence to Federico Bilotta:** Department of Anesthesiology, Critical Care and Pain Medicine, "Sapienza" University of Rome, Rome, Italy; E-mail: bilotta@tiscali.it

stroke is relatively poor [1]. The purpose of this chapter is to provide our recommendations about ICU management of AIS.

## GENERAL SUPPORTIVE CARE AND TREATMENT OF ACUTE COMPLICATIONS

Currently 4 interventions in AIS supported by class I evidence: reperfusion therapy with the use of intravenous rt-PA within 4-5 h of symptom onset, the use of aspirin within 48 h of stroke onset, decompressive craniotomy for supratentorial hemispheric cerebral infarction and admission to a stroke unit [2]. Around 15-20% of patients require admission to an ICU to allow cares and interventions that cannot be provide on a stroke unit. There are not specific guidelines for ICU admission, but certainly the decreased conscious level , the need for mechanical ventilation and the intensive hemodynamic management, represents universal indications for admission to intensive care [3]. In the end, patients with massive stroke are admitted to ICU to facilitate organ donation in those who have expressed a wish to donate (Table 1).

**Table 1. Criteria for ICU admission: our recommendations.**

Need for intubation and/or mechanical ventilation
Severe Stroke (National Institutes of Health Stroke Score > 17)
Management complications of reperfusion therapy
Persistent elevated blood pressure [systolic > 220 mmHg (not undergoing thrombolysis) or > 185 mmHg (undergoing thrombolysis)] or low blood pressure < 90 mmHg
Management of organ support
Postoperatively following decompressive craniectomy
To facilitate organ donation in patients who have expressed a wish to donate

## Ventilation and Supplement Oxygen

Hypoxia is common after stroke. Hypoxia is determined by partial airway obstruction, aspiration, low ventilation, atelectasis and pneumonia. For these reasons, it is recommended continuous monitoring of oxygenation with pulse oximetry (SpO<sub>2</sub>) for all patients in the ICU. Although routine oxygen supplementation may seem intuitive, in literature is little know and more research is needed. In hypoxemic patients with AIS, recent AHA guidelines recommend

O<sub>2</sub> supplementation to rise SpO<sub>2</sub> > 94% [4]. The choice to keep normoxia include nasal cannula, Venturi mask, non-rebreathe mask, BIPAP, CPAP and, only as last choice, orotracheal intubation. The orotracheal intubation is indicated in patients with altered consciousness or with severe bulbar damage that causes airway compromise and the loss of protective reflexes. Others criteria are reported in the Table 2. Tracheostomy should be accomplished after 1 week of mechanical ventilation [5]. The mortality rate of intubated AIS patients was found to be between 40 and 80% and only a small percentage of patients improves after intubation [6]. At last, the use of hyperventilation to decrease PaCO<sub>2</sub> is a rapid way to reduce intracranial pressure (ICP) and may be tolerated for days in patients with severe brain edema. Indeed, hyperventilation (PaCO<sub>2</sub> to 30-35 mmHg) cause vasoconstriction and reduce cerebral blood volume and, thus, ICP. However, in patients with brain injury, prolonged hyperventilation could cause cerebral ischemia. In conclusion, the use of extreme hyperventilation is reserved for a short time to reduce ICP and the its routine application is generally considered detrimental. In effect, hypocapnia is associated with poor prognosis. There are not evidence about use of hypercapnia to increase cerebral perfusion and to improve AIS outcomes [7].

**Table 2. Criteria for mechanical ventilation: our recommendations**

Glasgow Coma Score $\leq$ 8
Critical airway compromise
To prevent aspiration pneumonia
Therapy for intracranial hypertension
Acute respiratory failure
Generalized tonic-clonic seizures or status epilepticus
Apneic episodes

### **Sedation and Analgesia**

Sedation and analgesia are often necessary in patients with brain edema after stroke to manage ICP, to improve endotracheal tube tolerance and patient-ventilator synchrony, to reduce cerebral metabolic rate of oxygen (CMRO<sub>2</sub>), to prevent delirium [8]. In the neurological ICU, sedation and analgesia are maintained by infusion of ipnotic agents, suchs as propofol, midazolam or

---

## The Trials and Tribulations of Ischemic Stroke Therapy

Arani Bose\*, Sophia S. Kuo, Jennifer Wong, John Lockhart and Siu Po Sit

*Penumbra Inc, One Penumbra Place, 1351 Harbor Bay Parkway, Alameda, California, USA*

**Abstract:** In this chapter, we focus on the recently published randomized controlled trials examining combined endovascular therapy with IV tPA *versus* IV tPA alone. In October 2014, the first evidence was presented from a randomized clinical trial conducted in the Netherlands showing the benefit of endovascular therapy in acute ischemic stroke secondary to emergent large vessel occlusion in the anterior circulation. Four randomized controlled trials later confirmed these results. The advances in techniques and devices which enabled these positive findings for intra-arterial therapy, including aspiration thrombectomy, stent retrievers, and combination strategies will be discussed herein. We will also consider where opportunities remain to maximize favorable outcomes while minimizing costs as these recent trial results are translated into clinical practice.

**Keywords:** Acute ischemic stroke, Endovascular therapy, Intra-arterial therapy, Mechanical thrombectomy, Randomized clinical trial, Reperfusion catheter, Stent retriever.

### OVERVIEW

Excellent reviews of historical acute ischemic stroke trials have been published, for example see Nogueira *et al.* [1], which also cover the introduction of intravenous fibrinolytic agents and intra-arterial therapy. In early 2014, a review article accurately described the evolution of intra-arterial approaches and tools for acute stroke therapy [2]. Thus, we will dwell in this chapter upon the more recent

---

\* Address correspondence to Arani Bose: Penumbra Inc, One Penumbra Place, 1351 Harbor Bay Parkway, Alameda, California, USA; E-mail: arani.bose@penumbrainc.com

studies, in particular those randomized clinical trials (RCT) comparing combined intra-arterial therapy (IAT) with IV tPA to standard medical management alone [3 - 9]. Endovascular approaches to stroke treatment have been available as a promising option for patients ineligible or refractory to IV thrombolytic therapy since 2004. Finally in late 2014, a watershed event in the acute ischemic stroke field was achieved when a large randomized controlled trial definitively demonstrated the benefit of IAT in acute stroke patients with evidence of proximal artery occlusion in the anterior cerebral circulation [3]. These findings were subsequently confirmed by four published randomized controlled trials, which were halted early due to lack of equipoise [4 - 7]. Two additional positive RCTs have been presented publicly as of this writing [8, 9].

## **DEVICES AND CLINICAL TRIALS IN ACUTE ISCHEMIC STROKE**

### **The Beginning of Mechanical Thrombectomy**

Acute stroke thrombectomy is ushering in the future of neurointervention. Around 87% of stroke is ischemic due to in-situ thrombosis, extracranial embolus, or other origins. Only 3-5% of stroke is a result of hemorrhage in the subarachnoid space due to aneurysm rupture. Although current neurointerventional treatment of stroke is restricted to large clot burdens, located within the proximal vessels of the Circle of Willis, and treated within eight hours of symptom onset, this subgroup still represents at least a ten-fold larger group than the whole of the treated aneurysm population. Ischemic stroke thrombectomy remains by far the largest opportunity for expansion in neuroendovascular research and development, as well as for positive impact on patients' survival and quality of life.

Mechanical thrombectomy of occlusions causing an acute ischemic event has been an accepted procedure since catheters were first placed in the neurovasculature. Catheter-based suction thrombectomy was first described by Gerhard Schroth as early as the late 1980's. Direct aspiration would remain central to neurointerventional thrombectomy from that time forward. By 2004, the first FDA-approved product specifically intended for thrombectomy in acute stroke patients was launched, called the Merci Retriever (Concentric Medical/Stryker Neurovascular). The first generation 'X' devices resembled a

wire with the shape of a corkscrew, which was placed inside the clot in an effort to engage it and retrieve out of the body. A balloon-tipped guide catheter would be delivered in the proximal internal carotid and inflated prior to fully withdrawing the Merci under “flow arrest” conditions. Aspiration was then applied on the balloon guide to capture residual emboli and thrombus not collected by the Merci. Later generations, including the “L” and “K-mini” devices, modified the configuration of the grabber wire, some adding suture strands to assist in retaining the thrombus. The Merci device was only moderately successful in the clinic because of challenges in realizing consistent success. Complete or mostly complete intracranial vessel reperfusion (TICI 2A-3 or TIMI 2/3) was achieved only 48% of the time in a major study [10].

### **Aspiration Thrombectomy Comes of Age**

Four years later, in December 2007, the Penumbra System (Penumbra, Inc.) gained approval in the United States for use in revascularization of acute stroke patients. The Penumbra System used aspiration as its primary method of action. A flexible, large bore microcatheter was deployed to the site of occlusion and aspiration applied directly on the lesion itself. However, the early Penumbra System catheters, the largest of which was 0.041 in internal diameter, were not quite wide enough to avoid becoming obstructed by the thrombus and so another component, a Separator, was introduced to clear the catheter lumen and to continually break up the thrombus ingested under aspiration. Without a Separator, the early microcatheters could clog, at times necessitating removal and re-access, prolonging procedural times. Thus by using a Separator, direct aspiration and clot capture were combined to facilitate continuous thrombectomy. The Penumbra System increased the rate of successful reperfusion to 82% in the Pivotal trial for FDA approval [11], and improving further to 87% in the real-world POST study [12]. A stent-like three-dimensional (3D) binary nitinol device known as the Separator 3D was launched in Europe in January 2012 as an additional component of this system. The Separator 3D was designed to engage a thrombus in a third radial dimension, as the open body of the 3D is compressed and then retrieved into a Reperfusion Catheter positioned at the proximal margin of the primary occlusion [13, 14].



# Evolution of Devices for Endovascular Thrombectomy in Acute Ischemic Stroke: From the Beginning to the ADAPT Technique

Simone Peschillo<sup>1,\*</sup> and Francesco Diana<sup>2</sup>

<sup>1</sup> Department of Neurology and Psychiatry, Endovascular Neurosurgery/Interventional Neuroradiology, 'Sapienza' University of Rome, Rome, Italy

<sup>2</sup> Department of Neurology and Psychiatry, Interventional Neuroradiology, 'Sapienza' University of Rome, Rome, Italy

**Abstract:** Acute ischemic stroke is a major cause of mortality and morbidity and its treatment has attracted great interest in the last decades. Innovative instruments such as stent-retrievers, intermediate catheters, and large-bore catheters have recently been introduced to perform endovascular thrombectomy. In cases of large vessel occlusion, this technique produces better results than intravenous pharmacological treatment.

In this chapter, we discuss the history of devices developed for thrombectomy, concluding with the state-of-the-art devices in each category.

**Keywords:** ADAPT technique, Aspiration, Mechanical thrombectomy, Stent.

## INTRODUCTION

The treatment of ischemic stroke has evolved radically in recent years. The introduction of drugs that act directly on the thrombus has profoundly modified the therapeutic paradigms. However, despite the significant results achieved, some patients, particularly those with occlusion of large vessels, have not had clear improvements. For this reason, research has led to the development of devices that

---

\* **Address correspondence to Simone Peschillo:** Department of Neurology and Psychiatry, Endovascular Neurosurgery/Interventional Neuroradiology, 'Sapienza' University of Rome, Rome, Italy; E-mail: simone.peschillo@gmail.com

can be used in such cases; starting in the new millennium, with the introduction of the Merci system, until the direct aspiration technique (ADAPT), we have witnessed considerable technical advances, all to the benefit of patients. Furthermore, recent trials have demonstrated the clear superiority of mechanical thrombectomy in cases of large vessel occlusion. In this chapter we retrace the entire history of the devices used in mechanical thrombectomy, up to ADAPT, which has been another step towards perfecting the technique.

It was calculated that nearly 75% of patients with an acute stroke and score >10 on the National Institutes of Health Stroke Scale (NIHSS) treated with intravenous tissue-type plasminogen activator (tPA) do not achieve complete revascularization, and only 8% have significant clinical improvement [4, 5]. Treatment with mechanical thrombectomy devices leads to higher rates of revascularization [6 - 8].

In the last few years endovascular neurosurgeons and interventional neuroradiologists, with the support of medical device companies, have developed new techniques to remove cerebral blood clots directly. In selected cases, stent-retrievers, aspiration devices and other tools ensure complete thrombus removal in a shorter time. As mentioned in other chapters, time is the critical issue.


Current guidelines concentrate on the “time to microcatheter”, not to delay of recanalization after microcatheter placement (procedure time). “Door to treatment” in  $\leq 180$  minutes is considered the standard of care (golden hour) for obtaining clinical success [1]. Past studies focused on recanalization as a measure of treatment success [2], but the concept of futile recanalization shifted attention to the creation of treatment time-efficient protocols. Time to recanalization depends on the type, dimension, and consistency of the thrombosis as well as comorbidities associated with the thrombosis, so the time to microcatheter could be considered a metric to monitor, not a threshold for acceptable performance.

A recent study tried to determine the relationship between procedure time and clinical outcomes [3], showing that procedure time is indeed a critical determinant of outcomes following endovascular treatment (Table 1).

Since the beginning of this century, different systems and devices have been used

to eliminate thrombi from the cerebral circulation (Table 2). First of all pharmacological intra-arterial thrombolysis, then retrievers in the form of metal baskets that could catch blood clots. These were followed by a new generation of clot-disruptors and then stents used as clot retrievers. Most recently, a new aspiration technique has been introduced, acting directly on the thrombus through a large-bore catheter.

**Table 1. The relationship between endovascular procedure time and clinical outcome (modified Rankin score, mRS) at discharge.**



Considering the mechanism of action, we can summarize thrombectomy strategies into six different classes:

- Pharmacological intra-arterial thrombolysis
- Clot-disruptors
- Clot-catchers
- Stent retrievers
- SRLA (Stent Retriever with Local Aspiration)
- ADAPT (A Direct Aspiration first Pass Technique)

**SUBJECT INDEX****A**

- Abdominal pain 292, 293, 324, 336, 338, 395
- ACE catheter 140, 515, 537, 538
- Acute ischemic stroke field 512
- Acute phase 4, 11, 13, 14, 16, 55, 58, 63, 69, 70, 73, 74, 76, 77, 79, 81, 86, 96, 97, 104, 190, 201, 277, 306, 315, 328, 342, 391, 441, 474, 490, 491  
stroke treatment 104
- Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) 426, 427, 428, 429
- Acute stroke 43, 74, 84, 95, 96, 98, 103, 156, 164, 289, 530, 537, 538
- Acute stroke patients 63, 95, 97, 99, 101, 107, 512, 513
- Adaptive immunity 34, 48, 49
- Agents, thrombolytic 100, 113, 132, 204
- AIS 122, 123, 130, 132, 134, 136, 139  
endovascular treatment of 122, 123, 132, 134  
treatment of 130, 136, 139
- Alberta stroke program early CT score 69, 106, 124, 126
- Alteplase 104, 105, 108, 111, 114, 115, 116, 123, 128, 131
- American heart association/american stroke association guidelines 96, 109, 111
- Aneurysms 177, 238, 240, 244, 246, 247, 249, 256, 258, 259, 264, 265, 266, 280, 319, 325, 326, 383, 441, 444
- fusiform 258, 280
- Angiographic abnormalities 295, 297, 301, 305, 306, 317, 318
- Angiography 199, 215, 301, 307, 309, 317, 332, 333, 387, 409, 427, 490, 491, 493  
                  fluorescein 332, 333, 427
- Angiokeratomas 394, 395, 396
- Angiopathy, transient cerebral arteriopathy and postvaricella 307
- Angioplasty 164, 165, 205, 208, 209, 222, 224, 225, 322, 477, 479
- Angiotensin-converting enzyme (ACE) 140, 143, 253, 400, 516, 538, 540
- Angiotropic large cell lymphoma (ALCL) 340, 341, 342, 343, 346
- Animal models 31, 38, 40, 46, 379, 403
- Anterior cerebral artery 19, 59, 67, 265, 271, 273, 274, 275, 276, 277, 297, 302, 303, 308, 309, 386, 421
- Anterior circulation 125, 126, 128, 130, 133, 139, 155, 161, 170, 266, 446, 511, 517
- Anterior circulation LVO, included 517, 520, 521
- Anterior circulation stroke patients 106
- Antibodies 329, 336, 411, 412, 413
- Anticoagulant treatment 9, 290, 419
- Anticoagulation 185, 199, 201, 203, 209, 289, 419
- Anticoagulation treatment 187, 203
- Antifosfolipid syndrome 376
- Antigen-presenting cells (APCs) 34
- Antiplatelet therapy 243, 271, 277, 417
- Antithrombin III 187
- Aortic arch 56, 71, 72, 252, 253, 319, 476, 478

**Ulo qpg'Rgæj kmq (Eds.)**

All rights reserved-© 2016 Bentham Science Publishers

*Subject Index*

*Hipvgtu'lp'Pgwtquwtigt, Vol. 3 769*

- Aortic dissection 98, 243, 252, 253, 279, 280, 281  
Aortic regurgitation 251, 252, 253, 319, 323  
Apoptosis 28, 29, 38, 40, 43, 44, 45, 46  
Apparent diffusion coefficient (ADC) 28, 75, 76, 197  
Arterial dissections 242, 243, 258, 280, 282, 285, 326, 403  
Arterial lesions 308  
Arterial occlusion 84, 114, 124, 126, 326, 506  
Arterial stenosis 217, 228, 238, 277, 306, 447  
Arteriolar wall hyper-fluorescence 333  
Arteriopathy 258, 259, 281, 307, 308  
Arteritis, giant cell 293, 309, 319, 320  
Aspiration 21, 133, 140, 141, 143, 144, 145, 204, 499, 513, 515, 529, 535, 537, 538, 540  
Aspiration catheter 20, 144, 515, 538  
Aspiration thrombectomy 511, 513, 514  
Atherosclerotic plaque 56, 228, 474, 480  
Atherosclerotic stenosis 474, 475, 490  
Autosomal dominant polycystic kidney disease (ADPKD) 263, 264, 265, 266
- B**
- Balloon guide catheter 134, 138, 534  
Basilar artery 62, 221, 227, 228, 279, 291, 303, 312, 313, 398, 399  
Bifurcation, carotid 242, 279, 286, 321, 476, 477, 478, 491, 534
- Blood-brain barrier (BBB) 4, 28, 32, 33, 35, 37, 78, 79, 505  
Blood transfusions 112, 424, 425, 504  
Brain imaging 190, 268, 269, 382  
Brain infarct 55, 174, 285, 421, 422, 448  
Brain MRI 271, 275, 296, 303, 308, 345, 399, 406, 408, 422, 428, 436  
Brainstem 326, 328, 329, 331, 344, 382, 387, 388, 389, 434, 437  
Brain surface 71, 274  
Brain tissue 5, 23, 28, 29, 38, 42, 46, 73, 86, 87, 174  
Branch retinal artery occlusions (BRAO) 329, 330, 332, 333
- C**
- CADASIL mutations 378, 379  
CADASIL patients 379, 380, 382, 438  
CAD patients 280, 281, 282, 283, 284, 288, 291  
connective tissue of 282, 288  
Cannabis 302, 445, 446, 447  
Carotid arteries, common 252, 253, 279, 285, 478  
Carotid atherosclerosis 403, 474  
Carotid axis 385, 386, 387  
Carotid canal 259, 482, 483, 484, 491  
Carotid-cavernous fistula 246, 247, 249  
Carotid dissections 281, 287, 474, 490, 493  
Carotid occlusion, bilateral 30, 39  
Carotid stenosis 10, 474, 476, 478, 486  
Carotid stenting 474, 475, 476, 477, 478, 486, 487, 493  
Carotid stents 478, 479, 481, 482, 493

- Carotid Wallstent 479, 480, 487, 493
- Catheter 131, 132, 140, 144, 146, 147, 204, 205, 217, 301, 478, 486, 490, 491, 492, 512, 515, 516, 534, 536, 537, 540, 542
- coaxial 140, 146
- distal access 491, 492
- guiding 478, 486, 490
- thromboaspiration reperfusion 146
- Cavernous sinus 189, 190, 200, 246
- Cell death 4, 23, 28, 29, 30, 35, 43, 44, 45
- programmed 23, 28, 35, 43, 44
- Central Nervous System (CNS) 5, 189, 257, 270, 291, 292, 293, 294, 295, 298, 304, 340, 341, 344, 346, 401, 402, 416, 430, 443
- Cerebral amyloid angiopathy (CAA) 297, 298, 387, 438
- Cerebral angiography 217, 219, 239, 240, 247, 265, 270, 271, 273, 274, 275, 276, 288, 295, 297, 302, 303, 305, 313, 343, 386, 389, 398, 414, 441, 444
- Cerebral arteries 19, 28, 30, 56, 58, 66, 67, 68, 82, 106, 116, 124, 170, 171, 172, 173, 174, 176, 177, 217, 258, 265, 268, 269, 273, 277, 279, 301, 303, 308, 326, 378, 408, 415, 416, 421, 422, 423, 431, 441, 446, 448, 487, 491, 515, 534, 538
- Cerebral arteriopathy 258, 259, 307, 424
- Cerebral artery territory 70, 106, 171, 173
- Cerebral blood flow (CBF) 4, 23, 24, 25, 30, 56, 57, 73, 128, 194, 218, 276, 445, 487, 506, 537
- Cerebral blood volume (CBV) 31, 57, 128, 500
- Cerebral edema 194, 304, 498, 502, 504, 505
- Cerebral infarction 64, 78, 84, 109, 156, 157, 173, 237, 273, 341, 376, 394, 414, 436, 499, 540
- Cerebral ischaemia 55, 274, 414, 417, 419
- Cerebral ischemic lesions and stroke 268
- Cerebral small vessel diseases 237, 376
- Cerebral vasculitis 237, 272, 330, 334, 341, 346, 404, 427, 429, 441, 444
- Cerebral veins 193, 195, 199, 201
- Cerebral venous sinus thrombosis (CVST) 190, 209
- Cerebral venous thrombosis (CVT) 186, 189, 190, 195, 196, 198, 199, 200, 201, 202, 203, 204, 205
- Cerebrovascular complications 246, 252, 257, 396, 397, 398, 413, 420, 441, 448
- Cerebrovascular disease, consecutive patients 414
- Cervical arterial dissection (CAD) 278, 280, 281, 282, 283, 284, 285, 286, 288, 289, 291
- Cervical artery dissection 241, 246, 278, 284
- Cervical artery dissection and ischemic stroke patients (CADISP) 284
- Cervical segment 483, 484, 485

*Subject Index*

*Ht qpvgt u'lp 'P gwt quwti gt {, Vol. 3 76;*

- Clopidogrel 9, 222, 223, 226, 228, 271, 335, 400, 488, 489, 490
- Clot, thromboembolic 129, 131, 132, 146
- Clot-disruptors 531, 534
- Clot integration 138, 139
- CNS vasculitis 294, 305, 341, 343, 346
- Cogan's syndrome 299, 336, 337, 338, 339
- Cognitive impairment 268, 269, 295, 303, 346, 379, 407, 421, 422
- COL4A1 disease 386, 387
- COL4A1 mutations 386, 439
- Combination chemotherapy 343
- Combination group 115
- Common carotid artery (CCA) 252, 253, 279, 285, 321, 478, 482, 486
- Comparison of patient inclusion criteria and treatment methods 520
- Complete recanalization 115, 153, 165, 171, 172, 197, 289
- Computed tomography (CT) 55, 58, 63, 64, 65, 70, 74, 78, 79, 81, 87, 101, 125, 128, 131, 156, 160, 161, 174, 175, 185, 190, 194, 195, 198, 200, 201, 215, 251, 258, 270, 317, 341, 520, 521
- Computed tomography angiography (CTA) 55, 63, 70, 71, 87, 126, 127, 129, 130, 137, 217, 218, 219, 228, 243, 301, 305, 518, 520, 521, 522
- Concentric medical 533, 534, 535
- Concentric thrombus retriever 153, 154, 157
- Connective tissue disorders 249, 281, 282, 288, 291, 334
- Contraindication 69, 85, 107, 108, 109, 111, 200, 208, 209, 243, 316
- Conventional angiography 242, 286, 290, 301, 304, 305, 308, 313, 314, 320, 328, 343, 345, 421
- Cornea verticillata 394, 395, 396, 398
- Corpus callosum 248, 249, 331, 332, 334, 345, 392, 442
- Cortical spreading depression (CSD) 26, 27, 39, 435
- Cortical vein thrombosis 189, 190
- Corticosteroids 202, 271, 315, 316, 321, 328, 329, 344, 430, 432
- Corticosteroid therapy 314, 316, 341
- CSF analysis 302, 343, 346
- CT angiography 59, 63, 66, 73, 114, 127, 130, 160, 216, 218, 243, 249, 253, 255, 275, 288, 289, 304, 308, 314, 320, 328, 332
- CT perfusion 55, 63, 73, 114, 128, 131, 161, 218, 219
- CT scan 69, 74, 80, 85, 190, 195, 261, 270, 276, 301, 304, 327, 381, 391, 408, 487, 489
- CT venography 195, 200
- CVT, endovascular management of 203, 204, 205, 209
- Cyclophosphamide 271, 295, 300, 302, 321, 328, 334, 339, 429, 432
- Cytokines 33, 36, 48, 49
- Cytotoxic edema 26, 28, 57, 64, 81, 197
- D**
- Decompressive craniectomy 95, 170, 173, 174, 175, 176, 177, 179, 498

- Deep vein thrombosis (DVT) 325, 430, 504
- Defined PACNS 294, 297, 302
- Dendritic cells (DCs) 34
- Devices 122, 123, 145, 515, 516  
adjunctive 145, 515, 516  
important technological upgrading of 122, 123
- Diabetes mellitus 8, 9, 108, 228
- Diagnosis of Behçet disease 325, 326
- Diagnosis of FMD 242
- Diagnosis of moyamoya disease 274, 276
- Diagnosis of Takayasu arteritis 317
- Diffusion weighted imaging (DWI) 59, 61, 62, 65, 69, 74, 75, 76, 77, 81, 83, 84, 106, 171, 197, 200, 216, 217, 343, 392
- Digital subtraction angiography (DSA) 126, 127, 129, 137, 195, 198, 199, 200, 208, 219
- Direct aspiration 20, 21, 140, 143, 146, 147, 512, 513, 515, 524, 531
- Disability-adjusted life years (DALYs) 3, 14
- Disease 8, 10, 12, 14, 16, 37, 43, 67, 122, 152, 177, 178, 186, 188, 239, 242, 257, 260, 261, 262, 263, 266, 269, 272, 282, 283, 288, 294, 298, 299, 300, 307, 312, 320, 323, 324, 325, 329, 331, 334, 335, 336, 337, 338, 340, 342, 343, 344, 346, 376, 377, 378, 379, 380, 381, 382, 384, 386, 387, 388, 389, 390, 392, 393, 396, 398, 404, 420, 421, 424, 425, 428, 431, 475, 476  
autoimmune 37, 329, 336  
cardiovascular 8, 10  
carotid 475, 476  
complex 283  
extent of 342  
neuro-Behçet's 344, 346  
occlusive arterial 261, 262  
renal 396, 398  
sickle cell 272, 376, 404, 421  
sickle-cell 420, 421, 424, 425  
significant medical 122  
systemic 298, 299
- Disorders 10, 238, 240, 243, 246, 254, 256, 263, 266, 273, 291, 293, 294, 295, 297, 298, 299, 309, 317, 318, 319, 320, 329, 341, 376, 377, 383, 386, 387, 388, 389, 390, 393, 400, 403, 406, 407, 408, 409, 410, 429, 433, 435, 438, 439  
metabolic 237, 376, 408  
mitochondrial 406, 407, 409, 439
- Doppler sonography 278, 285, 286, 289, 291
- Dstenosis 220, 221
- Dural arteriovenous fistulas 189, 199
- Dural sinus 185, 190, 193, 197, 199, 200, 304, 326, 328, 329
- Dural sinus thrombosis 199, 304, 326, 328, 329
- DWI images 77, 80
- E**
- Edema, vasogenic 27, 28, 58, 67, 78, 200, 407
- Emergency management of stroke (EMS) 132
- Encephalo-myo-synangiosis 170, 177



- Encephalopathy 97, 186, 329, 330, 331, 332, 333, 335, 406, 502
- Enderectomy 8, 9, 474, 475, 476, 477, 486, 493
- Endothelial cells 27, 28, 32, 33, 37, 38, 48, 330, 392, 394, 429, 430
- Endovascular approach 122, 152, 158, 160, 161, 166, 512, 524
- Endovascular arm 129, 154, 155, 156, 158, 159, 160, 161, 162, 163
- Endovascular revascularization therapy (ERT) 124, 400
- Endovascular stroke treatment 123, 125, 134
- Endovascular techniques 185, 209, 475, 478, 542
- Endovascular therapy 125, 130, 153, 154, 155, 157, 162, 163, 164, 224, 249, 322, 511, 516
- Endovascular treatment 3, 16, 18, 19, 20, 122, 124, 129, 130, 160, 177, 185, 204, 205, 224, 259, 474, 476, 477, 488, 491, 492, 519
- Endovascular treatment for acute ischemic stroke 130
- End stage renal disease (ESRD) 263, 264, 396
- Endvascular treatment 185
- Energy metabolism 24, 25, 41
- European carotid surgery trial (ECST) 474
- European cooperative acute stroke study (ECASS) 102
- F**
- Fabry disease 376, 377, 394, 395, 398, 399
- Familial hemiplegic migraine (FHM) 438
- Fibrinolysis, venous 3, 16, 17, 18, 19
- Fibrinolytic therapy 69, 71, 87, 502
- Fibromuscular dysplasia 238, 239, 240, 241, 258, 281, 298, 317, 319
- First generation thrombectomy devices 152, 157
- FLAIR images 83, 297, 327
- Focal dissection 241, 288, 289
- G**
- Gadolinium enhancement 342, 343, 344, 345
- Gastrointestinal tract 260, 262, 292
- Genetic disorder 237, 256, 376
- Giant cell arteritis (GCA) 293, 309, 310, 311, 312, 314, 315, 316, 319, 320
- Global ischemia 29, 30
- Granulomatous angiitis of the CNS (GACNS) 294, 295, 297
- H**
- Haemorrhages 8, 79, 80, 85, 487, 488
- Haemorrhagic stroke 11, 274, 437, 440, 443
- HANAC syndrome 385, 386
- Health Stroke Scale 63, 155, 172, 530
- Hearing loss 255, 329, 330, 331, 335, 336, 337, 339, 406

- permanent 335, 337, 339  
 Heart disease and stroke statistics 11  
 Hematoma 110, 274, 279, 280, 286, 288, 302, 303  
   intramural 279, 280, 286, 288  
 Hemiplegic migraine (HM) 433, 434, 435, 438  
 Hemorrhagic strokes 385, 386  
 Hemorrhagic infarction 79, 84, 85, 190  
 Hemorrhagic stroke 5, 11, 41, 55, 63, 64, 86, 170, 240, 264, 269, 277, 388, 397, 432, 441, 444, 447, 448  
 Hemorrhagic transformation 71, 79, 97, 98, 100, 101, 102, 103, 105, 106, 107, 109, 110, 111, 113, 116, 504  
   symptomatic 102, 103, 105, 106, 107, 111, 113  
 Homocysteine 400, 401, 402, 404, 405, 406  
 Homocystinuria 376, 377, 400, 401, 402, 403, 404, 405, 406  
 Hours of stroke 104, 142  
 Hours of stroke onset 114, 130  
 Hours of symptom onset 102, 114, 123, 137, 164, 171, 512  
 Hyperacute phase 63, 65, 66, 73, 74, 77  
 Hyperdense vessel signs 66, 68, 69  
 Hyperdensity 66, 68, 193  
 Hyperhomocysteinemia 187, 400, 403, 404  
 Hyperintense 74, 80, 81, 82, 83, 85, 196, 197, 327, 328, 392  
 Hypertension 228, 238, 257, 260, 262, 263, 264, 266, 269, 280, 293, 299, 318, 319, 322, 388, 399, 502  
 Hyperventilation 273, 277, 500  
 Hypodensity 59, 65, 66, 68, 70, 79  
 Hypointense 74, 75, 80, 82, 197, 327, 328, 382  
 Hypotension 96, 277, 400, 442, 486, 501, 502, 505  
 Hypothermia 23, 39, 41, 503, 504  
 Hypothesis 31, 37, 38, 155, 158, 225, 282, 336, 437, 516
- I**
- ICA dissection 278, 279, 284, 490  
 Imaging 55, 56, 63, 85, 155, 161, 185, 265, 272, 286, 304, 308, 322, 382, 386  
   diagnostic 55, 56  
 Imaging diagnosis 185, 190  
 Immune response 35, 47, 48, 49, 417  
 Immunosuppressive treatment 296, 333, 340, 429  
 Incidence of stroke 7, 397, 422  
 Inclusion criteria, key patient 517, 522  
 Increased risk of stroke 36, 421, 437, 439  
 Independent risk factors 8, 447  
 Internal carotid artery (ICA) 19, 60, 61, 124, 143, 164, 165, 173, 177, 239, 240, 241, 242, 248, 252, 255, 258, 265, 272, 274, 275, 276, 278, 279, 284, 285, 288, 289, 291, 299, 312, 313, 386, 421, 474, 477, 478, 479, 480, 482, 486, 492, 516, 517, 523, 538  
 International criteria for Behçet's disease (ICBD) 325  
 International normalized ratio (INR) 9, 111, 221, 222, 418, 419  
 International stroke trial III 103

*Subject Index*

*Ht qpvgt ulp P gwt qwt i gt {, Vol. 3 775*

- Interstitial keratitis 336, 337, 338, 340  
Interventional management of stroke (IMS) 129, 154, 517  
Intra-arterial therapy 86, 511, 517, 524  
Intra-arterial thrombolysis (IAT) 125, 128, 129, 153, 512, 516, 520, 521, 524, 531, 533  
Intracranial aneurysms 177, 241, 246, 252, 256, 262, 264, 265  
    family history of 264  
Intra-cranial arterial stenosis (ICAS) 215, 216, 217, 218, 220, 221, 222, 223, 224, 225, 226, 228, 229  
Intracranial hemorrhage, symptomatic 105, 106, 114, 115, 154, 164, 518, 519  
Intracranial hypertension 185, 208, 326, 408, 498, 500, 505  
Intrarterial stroke treatment base 131  
Intravenous rt-PA 101, 103, 107, 110, 115, 277, 289, 499, 502  
Intravenous thrombolysis 99, 100, 101, 104, 105, 107, 108, 109, 110, 116, 124, 533  
Ion gradients 24, 26, 27  
Ischaemic penumbra 55  
Ischaemic stroke 55, 115, 225, 307, 410, 437, 438, 440  
Ischemic accidents 4, 8  
Ischemic lesions 38, 63, 79, 80, 81, 177, 217, 255, 262, 268, 269, 271, 297, 313, 409, 422, 423, 428, 440, 443, 445, 446, 487  
Ischemic stroke 4, 11, 33, 55, 56, 64, 74, 78, 85, 86, 95, 96, 97, 100, 101, 104, 108, 113, 123, 131, 133, 152, 153, 164, 170, 171, 172, 226, 262, 269, 278, 280, 304, 397, 398, 402, 407, 408, 413, 421, 432, 440, 441, 443, 444, 446, 474, 491, 529  
Ischemic stroke thrombectomy 512  
Ischemic tissues 25, 98, 128, 174, 502, 504  
Ischemic tolerance 39, 40
- K**
- Kohlmeier-Degos disease 298, 299
- L**
- Lacunar infarcts 58, 81, 220, 380, 382, 385, 387, 389, 391, 399, 437  
Lacunar strokes 56, 258, 377, 404  
    recurrent 270, 388  
Large vessel obstruction (LVO) 19, 20, 123, 124, 128, 129, 130, 133, 139, 142, 143, 147, 152, 153, 154, 155, 156, 166, 167, 516, 517, 520, 522, 524  
Large vessel occlusion 18, 19, 122, 123, 125, 129, 145, 152, 153, 158, 414, 515, 516, 524, 529, 530  
Lentiform nucleus 71, 72, 81  
Leukoencephalopathy 377, 384, 386, 387, 391, 392, 439  
Livedo racemosa (LR) 266, 267, 268, 270  
Low molecular weight heparin (LMWH) 420, 504  
Lumbar puncture 187, 188, 202, 333, 428  
Lymphocytes 33, 34, 35, 48, 49, 340, 430

**M**

- Macrophages 32, 33, 34, 35, 38, 80, 282
- Magnetic resonance angiography (MRA) 55, 59, 60, 61, 69, 74, 126, 127, 129, 156, 166, 171, 215, 217, 218, 219, 227, 228, 249, 276, 301, 305, 307, 308, 320, 328, 421, 422, 423
- Magnetic resonance imaging (MRI) 31, 55, 58, 61, 71, 73, 80, 81, 82, 83, 131, 156, 173, 174, 185, 195, 196, 198, 199, 200, 201, 251, 259, 262, 270, 276, 284, 285, 286, 295, 296, 297, 309, 312, 317, 320, 326, 327, 328, 331, 342, 345, 379, 380, 389, 399, 409, 414, 421, 423, 428, 431, 437, 440, 520, 521
- Major development of drugs and devices 122, 123
- Mannose-binding lectin (MBL) 46, 47, 48
- Marfan syndrome 238, 248, 250, 251, 252, 253, 279, 282, 285, 288, 319, 388, 403
- Maximum intensity projection (MIP) 72, 195, 255
- Mean flow velocity (MFV) 217, 444
- Mean transit time (MTT) 57, 128
- Mechanical thrombectomy 20, 122, 124, 132, 154, 155, 156, 161, 162, 163, 165, 203, 204, 205, 206, 208, 511, 512, 521, 524, 529, 530, 533, 534, 539
- Mechanical ventilation 499, 500, 502
- Medical treatment 221, 280, 289, 339, 481
- MELAS patients 406, 407
- MELAS-syndrome 407, 408
- Merci devices 134, 139, 205, 209, 513, 534, 535, 538
- Mesenchymal stromal cells (MSCs) 38
- Methionine 400, 401, 404, 405
- Methotrexate 300, 316, 321, 334, 339, 346
- Microangiopathy 329, 330, 376, 377, 392, 407  
cerebroretinal 376, 377, 392
- Microcatheter 132, 134, 135, 136, 138, 140, 146, 513, 515, 530, 533, 534, 535, 537, 538
- Microglia 31, 32, 34, 35, 36, 37, 38
- Microsurgical embolectomy 170, 171
- Middle cerebral artery (MCA) 59, 66, 67, 68, 71, 164, 217, 219, 269, 273, 274, 276, 515, 517, 523
- Migraine 8, 26, 189, 246, 280, 330, 379, 385, 407, 417, 432, 433, 434, 435, 436, 437, 438, 439, 444  
basilar 433, 434, 438  
hemiplegic 433, 434  
vestibular 434
- Migraine attacks 432, 437, 438
- Migraine–Stroke Association 439
- Migrainous infarction 376, 435, 436, 437
- Migrainous stroke 435
- Mimic PACNS 295, 298, 299, 307
- Mitral valve prolapse 251, 252, 260, 262, 264
- Modified rankin scale score 17, 102, 104, 269, 535, 538, 540
- Motor weakness 414, 433, 434

- Moyamoya disease 176, 257, 271, 272, 273, 274, 276, 298, 308, 309
- MR angiography 127, 243, 247, 248, 253, 258, 286, 287, 290, 303, 304, 308, 312, 314, 332, 403, 404, 415, 421, 423, 428, 436, 448
- MR images 331, 332, 342, 343
- MR rescue 129, 133, 152, 153, 155, 156, 516
- MR venography 193, 195, 196, 198, 304
- Multifocal FMD 239, 242
- Multiple sclerosis (MS) 76, 270, 299, 327, 328, 331, 333, 334, 341, 346, 392, 414, 417
- Muscle biopsy 330, 406, 408, 409
- N**
- National institute of health (NIH) 124, 154, 155
- National institute of health stroke scale score (NIHSS) 124, 142
- National institute of neurological disorders and stroke (NINDS) 100, 153
- Necrosis 23, 28, 29, 45, 46, 330
- NeuroBehcet disease (NBD) 323, 325, 326, 327, 328
- Neurocritical care 498
- Neurological disorders and stroke 153, 155
- Neurological institute of health stroke scale (NIHSS) 63, 86, 101, 114, 124, 130, 155, 161, 164, 166, 172, 179, 521, 530
- Neuromonitoring 498, 506
- Neurosurgeon 171, 177, 202
- Neurovascular-Behçet disease 326, 328
- Non-enhanced CT (NECT) 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 79, 82, 86, 216
- North American symptomatic carotid endarterectomy trial (NASCET) 474
- Nucleus tractus solitarius (NTS) 37
- O**
- Optical coherence tomography (OCT) 333, 334
- Optic neuropathy 311, 312, 338, 417
- Osteogenesis imperfecta (OI) 254, 255, 256, 288
- P**
- Patent foramen ovale (PFO) 9, 421, 435, 436, 437, 439
- Pattern recognition receptors (PRRs) 34
- Pediatric patients 177, 273, 276, 394, 403
- Penumbra pivotal stroke trial 142
- Penumbra System (PS) 20, 21, 141, 142, 143, 144, 155, 205, 513, 514, 521, 535, 536, 538
- Phenylpropanolamine 302, 447, 448
- Pittsburgh response to endovascular therapy score (PREs) 124
- Polyarteritis nodosa 270, 293, 299, 338, 341
- Posterior cerebral artery 60, 268, 269, 308
- Post ischemic inflammation 23

- Post-Varicella angiopathy (PVA) 307, 308, 309
- Prednisone 315, 321, 328, 339, 346
- Presymptomatic screening 264, 265, 266
- Preventing recurrent stroke 222, 418
- Preventing recurrent stroke in intracranial stenosis 222
- Primary endovascular treatment for acute ischemic stroke 163
- Primary prevention 7, 8, 418, 425
- Programmed cell death (PCD) 23, 28, 35, 43, 44, 46
- Prolyse in Acute Cerebral Thromboembolism (PROACT) 125, 128, 533
- Protein 44, 187, 250, 270, 343
- Proteinuria 188, 391, 394, 395, 396, 400
- Pseudoaneurysm 291, 493
- R**
- Reactive oxygen species (ROS) 32, 33, 46
- Recanalization rates 114, 115, 116, 122, 123, 133, 157, 158, 189, 538
- Renal failure 323, 391, 396, 501, 505
- Reperfusion 28, 33, 40, 46, 76, 77, 95, 96, 100, 114, 128, 131, 140, 513, 514, 515, 516, 517, 518, 520, 522 successful 100, 513, 515, 517
- Reperfusion catheter 141, 142, 143, 511, 513, 514, 535
- Reperfusion therapy 126, 498, 499
- Reported cases 204, 330, 427
- Revascularization 16, 18, 125, 139, 140, 142, 144, 145, 157, 158, 164, 275, 322, 513, 516, 530, 540
- Reversible cerebral vasoconstriction syndrome 237, 298, 300, 301, 302, 303, 440, 444, 445, 448, 449
- Reversible cerebral vasoconstrictive syndrome (RCVS) 294, 297, 300, 301, 302, 304, 305, 306
- Risk factors for migrainous stroke 435
- Risk factors Prevention 4
- Risk of stroke 7, 8, 9, 36, 223, 224, 228, 422, 424, 436, 437, 438, 439
- Rt-PA treatment 102, 105
- Rupture, arterial 246, 247, 249
- S**
- Segmental mediolytic arteriopathy (SMA) 281
- Severe stenosis 9, 217, 219, 228, 240, 291, 482, 483, 484, 485, 489, 491, 492
- Sinuses 187, 193, 194, 195, 196, 197, 199, 251 thrombosed 196, 197
- Sinus thrombosis, venous 195, 199
- Skin biopsies 262, 267, 270, 281, 282, 288, 380, 431
- Skin lesions 260, 325, 431, 432
- Small vessel disease 258, 261, 299, 377, 378, 383, 385, 386, 399, 414, 440
- Small-vessel occlusion 443
- Sneddon syndrome (SS) 208, 209, 266, 267, 268, 269, 270, 271, 439

*Subject Index*

*Ht qpvgt u'hp 'P gwt qwti gt{, Vol. 3 779*

- Solitaire FR 135, 136, 138, 157, 163, 514  
Solitaire stent retriever 152  
Solitaire stents 137, 538  
Solitaire with intention for thrombectomy (SWIFT) 136, 138, 152, 157, 163, 164, 514, 518, 520, 521, 522  
SRLA techniques 540  
Stenosis 9, 71, 215, 216, 217, 220, 221, 222, 224, 225, 226, 228, 238, 258, 272, 276, 290, 291, 303, 308, 312, 313, 314, 319, 320, 321, 322, 323, 326, 378, 409, 421, 430, 448, 477, 478, 479, 482, 483, 484, 485, 486, 487, 489, 491  
    critical 323  
    residual 224, 478, 479  
Stenosis progression 228  
Stent 152, 157, 158, 479, 480, 481, 482, 483, 484, 485, 481  
    balloon-expandable 482, 483, 484, 485  
    open cell 479, 480, 481  
    retrievable 152, 157, 158  
Stenting 157, 164, 165, 204, 222, 224, 225, 227, 244, 290, 313, 476, 477, 478, 483, 486, 488, 492  
    primary 157, 483  
Stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) 222, 223, 225, 226  
Stent-retriever-local-aspiration (SRLA) 20, 514, 520, 531, 537, 540  
Stent retrievers 128, 145, 161, 511, 514, 515, 516, 521, 524, 531, 536, 537, 538, 540  
Streaks, angiod 260, 261, 262  
Stress, oxidative 23, 40, 46  
Stroke 7, 59, 60, 63, 68, 71, 78, 95, 105, 106, 155, 220, 237, 238, 280, 376, 394, 398, 419, 435, 441, 445, 476, 486, 498, 499, 504, 517, 538  
    cause 237, 238, 376, 441  
    common mechanism of 220  
    cryptogenic 394, 398, 419  
    malignant 59, 95  
    massive 498, 499  
    periprocedural 476, 486  
    posterior 60  
    posterior circulation 106, 398, 538  
    risk factors for 7, 280, 435, 445  
    severe 63, 68, 105, 155, 499, 504, 517  
    suspected 71, 78  
Stroke care 85, 99, 100, 117  
Stroke clots 129, 155  
Stroke diagnosis 56  
Stroke etiologies 284  
Stroke event 177, 201, 215, 222, 229  
    recurrent 222  
Stroke-like episodes (SLEs) 269, 406, 407, 408, 410, 413, 415, 418, 439  
Stroke mechanism 220, 399  
Stroke mimics 97, 111  
Stroke onset 28, 97, 98, 102, 114, 115, 116, 125, 130, 131, 154, 267, 379, 499, 518  
Stroke patients 14, 16, 18, 19, 95, 99, 100, 102, 106, 109, 110, 115, 116, 117, 153, 155, 158, 160, 161, 237,

- 376, 405, 414, 416, 440, 443, 446, 447, 503, 505, 516, 517  
 acute ischemic 106, 153, 443, 517  
 consecutive 447  
 eligible acute 158  
 ischemic 115, 405, 516  
 management of acute 95, 99  
 randomized acute 155  
 selected acute ischemic 161  
 thrombolysed 110  
 Stroke prevention 153, 221, 222, 225, 405, 424, 425  
   secondary 153, 405, 424  
 Stroke recurrence 222, 223, 418  
 Stroke risk, increased 445  
 Strokes and TIA 8, 427  
 Stroke severity 62, 99, 101, 102, 105, 110, 123, 201  
 Stroke subtypes 100, 201, 524  
 Stroke survivors 10, 16  
 Stroke symptom onset 135, 309  
 Stroke thrombectomy, acute 143, 512  
 Stroke treatment 16, 130, 131, 512, 539  
   nechanicalendovascular 130  
 Stroke trials 112, 511  
   historical acute ischemic 511  
 Subarachnoid hemorrhage 199, 226, 240, 244, 246, 252, 285, 289, 301, 304  
 Susac's syndrome 299, 329, 330, 331, 332, 333, 334, 335  
 Susceptibility weighted imaging (SWI) 126, 193, 196  
 Suspected cases of RCVS 304, 305  
 Symptomatic intracranial transformation 102, 103  
 Symptoms of Fabry disease 394, 395  
 Syndrome 284, 304, 306, 338, 376, 377, 392, 411, 419, 422, 425, 429, 478, 486, 488, 501, 502  
   hyper-perfusion 478, 486, 488  
 Systemic vasculitis 292, 293, 294, 338, 339  
 Systems 79, 133, 136, 140, 144, 173, 175, 176, 338, 483, 513, 524, 530, 534, 535, 537, 538, 542  
   penumbra aspiration 535  
   ventricular 79, 173, 175, 176
- T**
- Takayasu arteritis 293, 311, 317, 321  
 Target INR 201, 289, 418, 419, 420  
 Temporal arteries 277, 278, 293, 310, 311, 314  
 Temporal artery biopsy 309, 314, 315  
 Thalamus 37, 60, 274, 297, 327, 331, 342, 345, 381, 382, 398, 409  
 Therapy 221, 271, 322, 333, 335, 339, 346, 432, 488  
   anticoagulant 221, 271, 488  
   immunosuppressive 322, 333, 335, 339, 346, 432  
 Thrombectomy 100, 136, 142, 152, 157, 163, 164, 167, 179, 185, 491, 512, 517, 529  
 Thrombectomy devices 518, 535, 537  
 Thrombectomy revascularization of large vessel occlusions in acute ischemic stroke 158  
 Thrombin time (TT) 111, 412  
 Thromboaspiration 145, 146, 205, 208  
   proximal 146  
 Thromboaspiration 185



- Thrombolysis 64, 85, 86, 95, 98, 101, 103, 107, 108, 109, 110, 111, 112, 113, 115, 125, 128, 129, 132, 133, 139, 153, 154, 161, 170, 171, 499, 506, 531, 533  
intra-arterial 125, 128, 129, 153, 531, 533  
undergoing 499
- Thrombolysis in cerebral infarction (TICI) 132, 133, 139, 144, 145, 147, 156, 157, 513, 515, 516, 517, 524, 540
- Thrombolysis in ischemic stroke 108
- Thrombolysis in myocardial infarction (TIMI) 128, 137, 142, 157, 513, 515, 517
- Thrombolytic therapy 95, 98, 102, 107, 111, 112, 113, 114
- Thrombophilia 187
- Thrombophlebitis 324
- Thrombosis 85, 112, 186, 189, 190, 194, 198, 199, 204, 208, 267, 277, 322, 326, 402, 404, 406, 410, 417, 418, 420, 431, 445, 530  
cerebral vein 204, 208  
vascular 402, 410
- Thrombus 20, 85, 126, 132, 134, 135, 136, 141, 142, 144, 145, 146, 190, 193, 194, 195, 196, 197, 198, 200, 203, 205, 417, 421, 513, 514, 515, 529, 531, 532, 535, 537, 538  
intravenous 193, 196, 197
- Thrombus in left ACM 135, 140, 146
- Thrombus removal 532, 534, 535
- Thunderclap headache 294, 301, 304, 306
- TIA-Stroke patients 228
- Ticlopidine 399, 489, 490
- Tinnitus 246, 330, 335, 337, 394, 434
- Tissue plasminogen activator, recombinant 122, 123, 204
- Toll-like receptors (TLRs) 34, 41
- Tortuosity 240, 241, 242, 247, 249, 255, 385, 386, 387, 476, 480  
arterial 240, 385, 386, 387
- Trans-cranial doppler (TCD) 116, 215, 217, 304, 305, 422, 423, 425, 506
- Transient cerebral arteriopathy (TCA) 307, 308, 309
- Transient ischemic attacks (TIA) 5, 8, 9, 58, 77, 225, 228, 268, 269, 271, 273, 285, 312, 320, 379, 413, 414, 416, 421, 427, 433, 435, 438, 441
- Transverse sinus, right 190, 193, 208, 404
- Treatment 8, 13, 95, 100, 107, 108, 116, 124, 129, 130, 132, 174, 177, 259, 266, 291, 325, 391, 417, 429, 475, 476, 477, 488, 498, 517  
aggressive 266, 429  
effective 116, 124  
intraarterial 130  
non-conservative 475, 477  
pharmacological 13, 488  
rapid 132, 517  
standard 129, 498  
steroid 325, 391  
surgical 8, 174, 177, 259, 291, 417, 476  
thrombolytic 95, 100, 107, 108
- Treatment of hypertension 8, 488
- Treatment of wake-up stroke 108
- Tromboaspiration 122, 139

**U**

278, 279, 280, 286, 288, 290, 309,  
312, 313, 484, 485, 489  
left 69, 247  
right 288, 313, 489

Ultrasonography 314, 320, 477, 532

Urokinase 125, 204, 208

**V**

Valve lesions 416, 417

Vascular complications 131, 256, 258,  
261, 403

Vascular disorders 237, 238, 241, 259,  
260

Vascular lesions 258, 259

Vascular manifestations (VMs) 260,  
261, 264, 312, 325, 396

Vascular network, abnormal 273, 275,  
276

Vascular occlusion 56, 57, 63, 113, 126,  
128, 137, 340

Vasculitis 57, 270, 291, 292, 293, 294,  
295, 296, 297, 298, 299, 305, 307,  
323, 326, 330, 338, 407, 426, 427,  
429, 440, 444

primary 292, 294

Vasculopathy 257, 269, 270, 417, 421,  
422

Vasoconstriction 301, 304, 305, 443,  
445, 446, 487

segmental 301, 304, 305

Vasospasm 139, 301, 303, 306, 435,  
444, 445, 448, 514

Venous infarction 67, 84, 85, 186, 194

Venous thrombosis 189, 190, 195, 196,  
403, 404, 416

Vertebral arteries 56, 69, 237, 238, 239,  
240, 241, 242, 247, 255, 256, 258,

Vertebrobasilar stroke 312, 434

Vessels 3, 16, 19, 20, 21, 32, 33, 34,  
109, 131, 134, 136, 143, 146, 194,  
216, 221, 224, 225, 260, 262, 278,  
279, 281, 286, 292, 293, 295, 314,  
342, 378, 424, 430, 476, 480, 481,  
482, 517, 529, 538

cerebral 109, 224, 225, 378

large 3, 16, 19, 293, 314, 342, 424,  
529

Vessel wall 21, 262, 279, 281, 314, 319,  
320, 330, 486, 491, 535, 537

Visual loss 186, 202, 311, 313, 314,  
315, 338, 433

Vitamin B6 402, 403, 404, 405

**W**

Warfarin 221, 222, 243, 418, 420

Warfarin aspirin recurrent stroke study  
(WARSS) 418

Warfarin aspirin symptomatic  
intracranial disease (WASID) 215,  
223, 228

WASID trial 220, 221, 222, 224

White arrow 193, 255, 287, 288, 290,  
302, 321, 381, 382, 387, 391

White matter 57, 65, 67, 74, 82, 267,  
270, 327, 329, 331, 332, 341, 342,  
380, 381, 382, 385, 387, 389, 391,  
393, 394, 398, 399, 400, 409, 414,  
437, 440, 442

*Subject Index*

*Hippokratu'Pgwqwtigt, Vol. 3 783*

- deep 270, 341, 380, 382, 387, 389, 391  
abnormalities 437, 440  
hyperintensities (WMHs) 380, 381, 382, 398, 399, 400, 437  
involvement 385, 387, 442  
lesions 341, 381, 389
- World Health Organization (WHO) 4, 7, 10, 12



**SIMONE PESCHILLO, M.D., PH.D.**

Born in Rome on December 20, 1978.

In the academic year 2003/2004 he graduated in Medicine and Surgery with 110/110 cum laude from the University of Rome "La Sapienza", with a thesis entitled: *The role of lumbar cerebrospinal fluid drainage in subarachnoid hemorrhage in patients with intracranial aneurysm underwent coil embolization* (Supervisor Prof. Roberto Delfini).

In 2005, he obtained authorization to practice medicine, and since then he was regularly admitted to the Rome Medical Association.

In the academic year 2008/2009 he obtained, the Certification in Neurosurgery at the University of Rome "La Sapienza", vote 70/70 cum laude, with a thesis entitled: *Endovascular treatment of cerebral aneurysms by using stents so-called "Flow diverter"* (Supervisor Prof. Giulio Guidetti).

In June 2013 he completed the PhD Course in Neurosurgery, Maxillofacial Surgery and Neuropathology of University of Rome "La Sapienza", with a thesis entitled: *Carotid-cavernous fistula: endovascular embolization through surgical access on the superior ophthalmic vein* (Tutor Prof. Giulio Guidetti).

Since January 2010 he has been working, in the Endovascular Neurosurgery/ Interventional Neuroradiology Department at University Hospital Umberto I° in Rome.

From 2008, he attended the Department of Interventional Neuroradiology Faculty of Medicine, Université de Nantes (France) directed by Prof. Axel de Kersaint-Gilly, the Department of Neuroradiology and Section of Interventional Neuroradiology Ospedale Niguarda - Ca 'Granda Milan (Italy) directed by Dr. Edoardo Boccardi and the Interventional Neuroradiology Department at University Hospital Umberto I° in Rome.

He participated as invited speaker to many conferences and congresses; furthermore he is the coordinator of many educational courses regarding Endovascular Neurosurgery.

Member since 2010 of the European Society of Minimally Invasive Neurological Therapy - ESMINT.

He is author of many articles published in international journals with high impact factors and Editor and co-author of various books.

He is also an ad hoc reviewer for several peer-reviewed journals.